2001

MedMira Receives "Review Complete" Notification from U.S. Food and Drug Administration for Reveal(TM) HIV Test: PRNewswire - December 27, 2001; HALIFAX, NS, Dec. 27 /PRNewswire/ - MedMira announced today that it has received official notification from the U.S. Food and Drug Administration ( FDA ) that it has completed its review on the Pre-Market Approval application for the MedMira Reveal(TM) HIV Test. The FDA has no further questions in relation to the pre-c
Doctors Sue NIH Over Controversial Cat Experiments: PRNewswire - December 27, 2001; WASHINGTON, Dec. 27 /PRNewswire/ -- The Physicians Committee for Responsible Medicine (PCRM) filed a lawsuit today against the federal National Institutes of Health (NIH) for concealing information about a controversial experiment involving live cats at Ohio State University (OSU) in Columbus. The experiments, conducte
AIDS Activist Larry Kramer Recovering Following Liver Transplant Surgery; Transplant Brings Focus to Issue of Co-Infection in Patients with HIV: PRNewswire - December 24, 2001; PITTSBURGH -- Larry Kramer, acclaimed writer and renowned AIDS activist, underwent liver transplant surgery on Dec. 21 at the University of Pittsburgh Medical Center (UPMC). Kramer, who has human immunodeficiency virus (HIV), needed the life-saving transplant because of end-stage liver failure caused by
Visible Genetics' Trugene Genotyping Technology Effective for Hepatitis B and C: PRNewswire - December 19, 2001; TORONTO, Dec. 19 /PRNewswire/ -- Visible Genetics Inc. (VGI, Nasdaq: VGIN) today presented results of comparative studies using its TRUGENE(TM) Hepatitis B virus (HBV) and Hepatitis C virus (HCV) genotyping tests at the international HEP-DART meeting in Hawaii. The results of one study demonstrated that the TRUGENE HBV
Studies Presented by Tibotec-Virco at ICAAC Highlight Promising Results in the Development of New HIV Therapeutic Compounds and the Increasing Importance of Resistance Testing: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Significant progress in the discovery and development of novel HIV therapeutics as well as the relevance of resistance testing systems in HIV management were highlighted by Tibotec-Virco scientists at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The
Female Health Company Announces Agreement: Total Access Group Gets Regional Exclusivity for Public Sector Sales: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) and Total Access Group (TAG) announced the appointment of Total Access Group as an exclusive distributor for Public Sector sales in 15 states in the western U.S. The objective is to increase access of FC to women most in need in areas
New Protease Inhibitor Atazanavir Combined With Saquinavir Once-Daily Is Effective and Safe In Protease Inhibitor Experienced Patients First Atazanavir Data in Experienced Patients; Beneficial Effects on Lipid Profiles: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- New data shows that the investigational protease inhibitor atazanavir can be used safely and effectively with saquinavir as part of a combination regimen in protease inhibitor-experienced HIV infected individuals, and that this regimen is similar in efficacy to one that includes
New Data Show Trugene(TM) HIV Resistance Test May Be Useful in 'Early Failures' and Before Treatment Is Started: PRNewswire - December 18, 2001; TORONTO, Dec. 18 /PRNewswire/ -- Visible Genetics Inc., (Nasdaq: VGIN) (VGI) announced that data presented today at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago indicate that Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test can be used to detect HIV drug resistance even
Boehringer Ingelheim Presents Late-Breaking Data on Tipranavir, First Non-Peptidic Protease Inhibitor (NPPI): PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Data presented today demonstrate the antiretroviral activity of tipranavir in HIV-positive patients whose first protease inhibitor (PI)-containing regimen was failing. Tipranavir is the first non-peptidic protease inhibitor (NPPI) in development for the treatment of HIV-1 infection. The
ViroLogic Announces New Study with Phenosense(TM) HIV Reveals Higher Than Expected Rate of HIV Drug Resistance In United States: Widespread Drug Resistance Supports Need for More Drug Resistance Testing: PRNewswire - December 18, 2001; SOUTH SAN FRANCISCO, Calif. and CHICAGO, Dec. 18 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the first national assessment of HIV drug resistance has revealed that 78 percent of HIV patients with measurable levels of virus in their blood are infected with an HIV strain that is resistant to one o
FDA Completes IND Review for Tibotec-Virco's Candidate Anti-HIV Drug, TMC125: Tibotec-Virco To Initiate Phase I Clinical Trial in the U.S.: PRNewswire - December 18, 2001; MECHELEN, Belgium , Dec. 18 /PRNewswire/ -- Tibotec-Virco announced that the U.S. Food and Drug Administration ( FDA ) has completed its review of the company s Investigational New Drug application (IND) for its candidate drug. TMC125 is a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI).
Encouraging Resistance Data in Anti-Retroviral Naive Patients Extended To Two Years For Abbott Laboratories' Kaletra (lopinavir/ritonavir) - Additional Kaletra Clinical Trials to Study Resistance Profile Underway -: PRNewswire- -December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Data presented today at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago shows drug resistance has yet to emerge in naive patients who have been taking Kaletra for 96 weeks. The study of patients new to HIV therapy showed that of those who experienced
Progenics' Experimental Drug, PRO 140, Provided Complete and Sustained Control Of HIV Infection In Vivo - Company's HIV Entry Inhibitors PRO 542 and PRO 140 Featured In Keynote Session At Major Scientific Conference -: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire / -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported that repeated doses of its experimental drug, PRO 140, reduced and then maintained viral loads at undetectable levels for the duration of therapy in a well-recognized animal model of HIV (human immunodeficiency virus) infection. S
New Study Suggests Suppressive Therapy With VALTREX(R) (Valacyclovir Hydrochloride) Caplets Once-A-Day Can Significantly Reduce Genital Herpes Outbreaks by Nearly 80 Percent Compared to Episodic Therapy: PRNewswire - December 17, 2001; CHICAGO, Dec. 17 /PRNewswire/ -- New research presented today at ICAAC suggests that managing recurrent genital herpes with VALTREX caplets for suppressive therapy -- treating daily before symptoms ever appear -- is significantly more effective at reducing the number of genital herpes recurrences or outbreaks than tr
Cangene files for anti-Hepatitis B product approval in Canada: PRNewswire - December 17, 2001; TORONTO/WINNIPEG, Dec. 17 /PRNewswire/ - Cangene Corporation (TSE:CNJ) announces that it has filed a New Drug Submission for its anti-Hepatitis B hyperimmune in Canada . The submission follows a U.S. licensing application filed earlier this year, and seeks Health Canada (Health Products and Food Branch) approval for us
Novirio Pharmaceuticals Announces Results From First Human Study of LdT for the Treatment of Hepatitis B Infection - Phase I/II Data Presented at the Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC) -: PRNewswire - December 17, 2001; CHICAGO, Dec. 17 /PRNewswire/ -- Novirio Pharmaceuticals yesterday announced at the 41st ICAAC Conference in Chicago results from the first human study of LdT, the company s new treatment for chronic hepatitis B virus (HBV) infection. Study results indicate rapid and profound reduction of hepatitis B virus replication
VaxGen to Present at Bay Area Biotech/Healthcare Forum on January 12, 2002: PRNewswire - December 17, 2001; BRISBANE, Calif., Dec. 17 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) will be among the companies featured at the Informed Investors Bay Area Biotech/Healthcare Forum on Saturday, January 12, 2002. The presentation will take place at 10:00 a.m. (PST) at the Radisson Hotel Berkeley Marina, 200 Marina Blvd., Berkeley, C
Achillion Pharmaceuticals Presents Phase 1 Data of ACH-126,443 at the 41st Annual ICAAC Conference - Lead Compound for the Treatment of Chronic Hepatitis B and HIV Infections: PRNewswire - December 17, 2001; NEW HAVEN, Conn., Dec. 17 /PRNewswire/ -- Achillion Pharmaceuticals, a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative anti-infective agents, presented Sunday at the 41st annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Achi
Study Compares PROCRIT(R) (Epoetin alfa) Once-Weekly vs. Three-Times-Weekly Dosing in Anemic HIV-Positive Patients on Antiretroviral Therapy: PRNewswire - December 17, 2001; CHICAGO, Ill., Dec. 17 /PRNewswire/ -- The results of an interim analysis of an open-label study to assess the effect of once-weekly (QW) dosing of PROCRIT(R) (Epoetin alfa) versus three-times-weekly (TIW) dosing in HIV- positive patients receiving antiretroviral therapy were presented today at the 41st annual meeting
amfAR Grantee Dr. Richard Kornbluth Receives GlaxoSmithKline Award for Breakthrough Idea in HIV/AIDS Treatment: PRNewswire - December 17, 2001; NEW YORK, Dec. 17 /PRNewswire/ -- On December 14, 2001, American Foundation for AIDS Research (amfAR) grantee, Richard Kornbluth, M.D., Ph.D., received a GlaxoSmithKline Drug Discovery and Development Award for developing a test to measure HIV integration, or the means by which HIV inserts itself into the genes of cell
Dynacare Offers Breakthrough Test to Help Doctors Find Better Treatment Options for HIV Patients: New Test Identifies Each Patient's Specific Type of HIV Infection; Leads To More Effective Drug Therapy Program: PRNewswire - December 17, 2001; DALLAS, Dec. 17 /PRNewswire/ -- Dynacare Inc. (Nasdaq: DNCR; Toronto: DNA) announced today that it is now offering a new genotyping test to help doctors find better treatment options for their patients affected with the human immunodeficiency virus (HIV). The test, TRUGENE (TM) HIV-1 Genotyping Test, is manufactured by
University of Pittsburgh and Pittsburgh VA Receive $8 Million To Study Alcohol and HIV Interactions: PRNewswire - December 17, 2001; PITTSBURGH, Dec. 17 /PRNewswire/ -- Alcohol is the most common drug of abuse among people infected with HIV. To study how alcohol use and abuse interacts with HIV infection and treatment, the University of Pittsburgh and the Pittsburgh Veterans Administration Medical Center have received an $8 million grant from the Na
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs: PRNewswire - December 14, 2001; LOS ANGELES, Dec. 14 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork for AIDS Project Los Angeles (APLA) 2001 holiday card campaign. Created through a partnership with Soolip Paperie & Press, the holiday c
Emerging Company Report; Patented HIV Treatment Showing No Side Effects in Trials: PRNewswire - December 14, 2001; HOLLYWOOD, Calif., Dec. 14 /PRNewswire/ -- Emerging Company Report is the nationally syndicated television program profiling emerging-growth companies ( http://www.emergingcompany.com ), featuring informative interviews with the CEOs, insights into their operations and outlooks for their futures. Free information packa
$250,000 in Unrestricted Grants From GlaxoSmithKline Support Breakthroughs In HIV/AIDS Treatment: PRNewswire - December 14, 2001; RESEARCH TRIANGLE PARK, N.C., Dec. 14 /PRNewswire/ -- A program awarding $250,000 in unrestricted grants to support innovations in the treatment or prevention of HIV-1 was announced today by GlaxoSmithKline (GSK). The GSK Drug Discovery and Development Award 2001 honors three researchers for their groundbreaking work t
Antiviral Summit to Feature New Section on Latest Vaccine Research, March 13-14, Princeton NJ: PRNewswire - December 13, 2001; PRINCETON, N.J., Dec. 13 /PRNewswire/ -- The world of antiviral researchers and clinical experts from the pharma & biotech industry will be convening in Princeton, NJ to attend, speak, & exhibit at the 3rd International Antiviral & Vaccine Discovery & Development Summit announces Strategic Research Inst
New Partnership to Accelerate AIDS Vaccine Testing, Equip Developing Countries for Trials: International AIDS Vaccine Initiative Opens Central Laboratory With Imperial College and Chelsea and Westminster Hospital: PRNewswire - December 13, 2001; LONDON, Dec. 13 /PRNewswire/ -- A new international public-private partnership will help ensure that promising candidates for a vaccine to prevent AIDS advance rapidly through human testing and that developing countries -- particularly in Africa and Asia -- have the supplies and training needed to conduct their own vac
MAC Cosmetics Announces Elton John, Mary J. Blige and Shirley Manson as the New Spokespeople for VIVA GLAM IV Lipstick and the MAC AIDS Fund: PRNewswire - December 13, 2001; NEW YORK, Dec. 13 /PRNewswire/ -- MAC Cosmetics, the rule-breaking professional cosmetics company, announced today music legend and outspoken AIDS activist Elton John, Grammy Award winner Mary J. Blige and rock icon Shirley Manson of the band Garbage have been named the spokespeople for VIVA GLAM IV lipstick. Since its
AIDS ReSearch Alliance of America Announces Landmark Agreement to Share Drug Revenues With Samoan Village Healers - Promising Rain Forest-Derived Anti-AIDS Compound Is First Ever Licensed by National Cancer Institute to a Non-Profit Research Institution: PRNewswire - December 13, 2001; WEST HOLLYWOOD, Calif., Dec. 13 /PRNewswire/ -- AIDS ReSearch Alliance of America (ARA) today announced a landmark agreement to return 20 percent of any commercial revenues from an experimental but promising anti-HIV compound called prostratin to the people of Samoa who helped American researchers discover
ViroLogic Announces Schedule of Presentations at the 41st Interscience Conference on Antimicrobial Agents and ChemotherapyCompany to Hold Conference Call to Discuss Impact of Latebreaker Study Results: PRNewswire - December 12, 2001; SOUTH SAN FRANCISCO, Calif., Dec. 12 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the presentation of four abstracts including one latebreaker at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place at the McCormick Place Lakeside Center from December 16-19, 2
Protein Sciences Announces Contact With The National Institute of Allergy and Infectious Diseases for Production of New HIV/AIDS Vaccines: Over $2 Million in Funding Already Approved and up to $76 Million Could Be Accessed: PRNewswire - December 12, 2001; MERIDEN, Conn., Dec. 12 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced today that it has signed a contract with the National Institute of Allergy and Infections Diseases (NIAID) that provides for up to $76 million in funding through mid-2006 for development and production of antigens for new vaccines for
Gold Fields Signs Landmark Agreements on HIV/AIDS in the Workplace and Competencies and Job Grading With Unions and Associations: PRNewswire - December 12, 2001; JOHANNESBURG, South Africa , Dec. 12 /PRNewswire/ -- Gold Fields Limited today signed landmark agreements on HIV/AIDS in the Workplace and Competencies and Job Grading with Unions and Associations representative of Gold Fields employees. The agreement on HIV/AIDS In The Workplace, which is a comprehensive response to H
WDI Expands Distribution and Sales in South Africa: Provides Healthcare Screening for Private Sector Companies: PRNewswire - December 11, 2001; MIAMI LAKES, Fla., Dec. 11 /PRNewswire/ -- World Diagnostics, Inc. (WDI), http://www.worlddiagnostics.com, a global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that its local distributor in Durbin has concluded agreements with AFROX, NAMPAK
Kaiser Family Foundation Survey: More Young People Going Online for Health Information Than to Shop, Check Sports Scores or Chat: Many Teen Health Seekers Blocked by Filtering Technology, but Two-Thirds Support It in Schools and Libraries: PRNewswire - December 11, 2001; NEW YORK, Dec. 11 /PRNewswire/ -- A new national survey by the Kaiser Family Foundation finds teens and young adults (ages 15-24) are not only going online to shop, talk to friends, or download music, but also to look up information about health issues from diabetes to AIDS. Two out of three young people (68%) have use
Gen-Probe and Chiron Settle Contractual Dispute: PRNewswire - December 11, 2001; SAN DIEGO, Dec. 11 /PRNewswire/ -- Gen-Probe Incorporated announced today that it and Chiron Corporation (Nasdaq: CHIR) have reached a negotiated resolution of all contractual disputes which were proceeding towards arbitration. This resolution was reached prior to the commencement of formal arbitration proceedings, whi
Hopkins Report: Youth Crucial to Stopping HIV/AIDS: PRNewswire - December 10, 2001; BALTIMORE, Dec. 10 /PRNewswire/ -- To stop the HIV/AIDS epidemic from becoming a catastrophe, prevention strategies must do much more to reach young people right away, according to a new report from the Johns Hopkins University Bloomberg School of Public Health. The Hopkins call for a youth-centered strategy follows gr
MedMira Amends Treatment Investigational Device Exemption: PRNewswire - December 7, 2001; HALIFAX, Dec. 7 /PRNewswire/ - MedMira announced it is in the process of filing an amendment to its current Food and Drug Administration ( FDA ) approved Treatment Investigational Device Exemption ( TIDE ) to include rapid HIV screening prior to smallpox vaccination. Increasing fear of bioterrorist actions involving th
Elizabeth Glaser Pediatric AIDS Foundation's Global Program to Prevent Mother-to-Child Transmission of HIV to Serve as Pilot Sites For New Initiative to Treat Women and Children With HIV/AIDS: PRNewswire - December 7, 2001; Elizabeth Glaser Pediatric AIDS Foundation Congratulates the Private Foundations for Their Unprecedented Collaboration and Expected $100 Million Commitment to MTCT-Plus WASHINGTON, Dec. 7 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) commends the private foundations expected to commit $100 mill
ViroLogic Announces Distribution Agreement with Esoterix for HIV Phenotypic Drug Resistance Testing: Leading Laboratory Service To Offer ViroLogic's HIV Phenotypic Line of Tests: PRNewswire - December 6, 2001; SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the Company has signed a distribution and marketing agreement with Esoterix Inc., a leading, privately held laboratory services company. ViroLogic will be the preferred provider of HIV phenotypic drug resistance testing f
CEL-SCI Corporation Announces Publication of Promising Preclinical Results: PRNewswire - December 5, 2001; VIENNA, Va., Dec. 5 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announces the peer-reviewed publication of important work in VACCINE (19(32) 4750-9). In the article, the researchers demonstrated that animals given CEL-SCI s experimental L.E.A.P.S. based HIV vaccine agent, showed strong evidence supporting the induc
Alicia Keyes, Gwen Stefani, Eve, *NSYNC and Other AAAW Supporters Put Global AIDS Pandemic as a #1 Priority for US Politicians at the Billboard Awards: PRNewswire - December 4, 2001; LAS VEGAS, Dec. 4 /PRNewswire/ -- Hot on the heels of its award for Best Collaboration at the VH1 Awards, Artists Against AIDS Worldwide is taking its call for urgent action to The Billboard Bash and Music Awards, to mark World AIDS Day. The message to the general public and politicians is clear: We have the know-how a
Lannett Company Receives FDA Approval for Isoniazid 300 mg Tablets: Used to treat Tuberculosis and as a preventative therapy for HIV: PRNewswire - December 4, 2001; PHILADELPHIA, Dec. 4 /PRNewswire/ -- Lannett Company, Inc. (OTC Bulletin Board: LANN), a manufacturer of pharmaceutical products, announced that the Food and Drug Administration has re-approved its Abbreviated New Drug Application (ANDA) for Isoniazid 300 mg tablets, which is an antibacterial drug used for Tuberculosis
Antibacterial, Antifungal, & Antiviral Drug Discovery Conferences To Take Place March 11-14, 2002 in Princeton, NJ: PRNewswire - December 3, 2001; PRINCETON, N.J., Dec. 3 /PRNewswire/ -- The World Antibacterial, Antifungal, & Antiviral research communities will convene in Princeton, NJ this coming March to attend the 7th Antibacterial Drug Discovery & Development Summit on March 11-12, and the 6th Antifungal Drug Discovery & Development Summit and 3rd
Pennsylvania Gov. Schweiker Administration Adds HIV Drug To Special Pharmaceutical Benefits Program: PRNewswire - December 3, 2001; HARRISBURG, Pa., Dec. 3 /PRNewswire/ -- On behalf of Pennsylvania Gov. Mark Schweiker, Public Welfare Secretary Feather O. Houstoun today announced the addition of Viread (tenofovir disoproxil fumarate) to the HIV/AIDS drug formulary of the state s Special Pharmaceutical Benefits Program (SPBP).
HUD Awards $6 Million to Assist People and Families Living With HIV/AIDS: PRNewswire - December 3, 2001; WASHINGTON, Dec. 3 /PRNewswire/ -- More than a thousand persons living with HIV/AIDS and their families will receive critically needed housing assistance and supportive services as a result of grants announced today by Housing and Urban Development Secretary Mel Martinez. The grants are part of HUD s Housing Opportunit
Black Media Launch Task Force to Respond to AIDS: AAAPTI Also Launches 'Heroes in the Struggle' Photo Exhibit: PRNewswire - December 1, 2001; LOS ANGELES, Dec. 1 /PRNewswire/ -- In an unprecedented commitment to the fight against AIDS, executives from the nation s leading black media companies today announced the formation of the Black Media Task Force on AIDS, a collaborative effort to increase AIDS awareness among the African-American community, and fight
Fusebox Launches Web Site Designed to Help Save the World's Youth: PRNewswire - November 30, 2001; NEW YORK, Nov. 30 /PRNewswire/ -- Fusebox has just launched a website for YouthAIDS (http://www.youthaids.org), a global initiative of Population Services International (PSI) to raise funds and awareness to stop the spread of HIV/AIDS among young people. Through education and the promotion and sale of affordable male a
Haiti: Inter-American Development Bank Continues to Block Health Loans - Approves Grant to NGO for HIV/AIDS: PRNewswire - November 30, 2001; WASHINGTON, Nov. 30 /PRNewswire/ -- Yesterday the Inter-American Development Bank approved a $1 million grant to the Pan American Health Organization (PAHO) for technical assistance to Haiti in the area of HIV/AIDS. On its face this grant would seem like the proper response to a growing and dramatic health crisis, but
World AIDS Day Announcement: The Balm In Gilead Launches International Program to Engage Churches in Six African Countries in Addressing AIDS: Nation's Only AIDS Organization Targeting Black Churches Now Expands Its Work To Churches in Sub-Saharan Africa: PRNewswire - November 30, 2001; NEW YORK, Nov. 30 /PRNewswire/ -- For World AIDS Day 2001, The Balm In Gilead, the nation s only organization dedicated exclusively to empowering churches to address HIV/AIDS in the Black community, announces the launch of its new international faith-based initiative. With funding from the Centers for Disease Control a
New Database on HIV/AIDS Nutrition with Soy Now Available on Internet: Soybean Farmers Offer Information in Conjunction with World AIDS Day: PRNewswire - November 30, 2001; ST. LOUIS, Nov. 30 /PRNewswire/ -- America s soybean growers are launching a new searchable database that will provide a rapid way to evaluate nutrition research and programs using soy for those living with HIV/AIDS. The database includes an annotated listing of citations. It can be searched at the website for the Worl
CONTINUOUS PROGRESS TO ADDRESS THE AIDS EPIDEMIC: Axios Celebrates World AIDS Day with Boehringer Ingelheim as Ukraine Becomes the First Country in Eastern Europe to Join the VIRAMUNE� Donation Program: PRNewswire - November 30, 2001; Dublin, Ireland , 30 November 2001 - On World AIDS Day 2001, Axios International reports on the successful progress of its partnership with Boehringer Ingelheim to address the HIV/AIDS epidemic in the developing world. The latest shipment of VIRAMUNE� was handed over to the
Stressgen announces robust HPV data from multiple Phase II clinical trials: Aggregate Data Support Broad Activity of HspE7 in Sexually Transmitted Diseases Caused by Human Papillomavirus: PRNewswire - November 29, 2001; VICTORIA, BC, Nov. 29 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE: SSB) announced the latest results compiled from six data sets from five key phase II clinical trials involving its lead fusion product, HspE7, a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus (
New TB Drugs Needed Alongside Antiretrovirals: Joint Approach of HIV and TB a 'Must,' As TB is Number 1 Killer of AIDS Patients: PRNewswire - November 29, 2001; NEW YORK, Nov. 29 /PRNewswire/ -- Fighting the converging epidemics of HIV/AIDS and tuberculosis (TB) will require improved anti-TB drugs as well as wide access to antiretrovirals, with an integrated approach to treating both diseases, according to the Global Alliance for TB Drug Development, a public-private partnersh
Female Health Signs Agreement for India: Major Marketer Plans to Register and Market Female Condom: PRNewswire - November 29, 2001; CHICAGO, Nov. 29 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed an agreement with Hindustan Latex Limited (HLL), India s largest male condom manufacturer. HLL also manufactures and markets a wide range of hormonal contraceptives. The agreement was signed in London, a
NIH Grant Helps Population Council Advance Promising HIV/AIDS Prevention Research: Support for 'Novel Anti-HIV Carrageenan-based Microbicides' Research May Result in More Options for Women to Protect Themselves From Infections: PRNewswire - November 29, 2001; NEW YORK, Nov. 29 /PRNewswire/ -- The U.S. National Institute of Child Health and Human Development (NICHD) has awarded a grant of $6.8 million to the Population Council to further its research on a promising HIV/AIDS prevention product. The funding is aimed at developing improved second-generation microbicides and at
Epimmune and Bavarian Nordic Combine Technologies to Develop HIV Vaccine: PRNewswire - November 29, 2001; SAN DIEGO and COPENHAGEN, Denmark , Nov. 29 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) and Bavarian Nordic A/S (Copenhagen: BAVA), announced today that they have entered into a collaboration agreement to combine their technologies to develop vaccines for the treatment or prevention of HIV infection. Under the agr
PAMBEC Laboratories Inc. Unveils New Anti-AIDS Drug: PRNewswire - November 29, 2001; FORT COLLINS, Colo., Nov. 29 /PRNewswire/ -- PAMBEC Laboratories Inc., of Loveland, Colorado today announced the release of a new Anti-AIDS drug AIDFAREL(TM) using a new drug technology invented by the company. This new technology shows great promise in permanently stopping the human immunodeficiency virus-1 (HIV-1), w
Artist Unveils Giant Painting on World AIDS Day for Children: Nearly an Acre in Size, the 41,400 Sq Ft Painting To Be Sold in Pieces for Charities: PRNewswire - November 28, 2001; RALEIGH, N.C., Nov. 28 /PRNewswire/ -- After five long years of planning and painting, international artist Eric Waugh will unveil Hero: The World s Largest Painting by One Artist for the first and only time on World AIDS Day, Dec. 1, 2001, to raise $4 million for Camp Heartland, a national non profit organization dedi
New AIDS Orphans Assistance Database (AOAD) Launched Before World AIDS Day 2001: PRNewswire - November 28, 2001; WASHINGTON, Nov. 28 /PRNewswire/ -- The Association Francois-Xavier Bagnoud (AFXB) and the World Bank Early Child Development Team announced today the launch of the revised AIDS Orphans Assistance Database (AOAD). The purpose of the AOAD is to facilitate communication among organizations and individuals worldwide which
World AIDS Day At The United Nations, November 30: `I Care ... Do You?' Highlights The Role of Volunteerism In Addressing the Epidemic: PRNewswire - November 28, 2001; UNITED NATIONS, Nov. 28 /PRNewswire/-- The United Nations Department of Public Information (DPI) and the Joint United Nations Program on HIV/AIDS ( UNAIDS ) are organizing an observance of World AIDS Day on 30 November 2001, 10:00 a.m. to 1:00 p.m. The town-hall meeting, I Care ... Do You?, will focus on the initiativ
New VA Research Looks at Alcohol and HIV Interaction: PRNewswire - November 27, 2001; WASHINGTON, Nov. 27 /PRNewswire/ -- Six medical centers of the Department of Veterans Affairs (VA) are joining forces in a major study to look at how excessive drinking impacts aging veterans with and without HIV (Human Immunodeficiency Virus) infection. Funded by the National Institute on Alcohol Abuse and Alcoholism
Americans are the World's Top Lovers... About 124 Times Each Year; The Fall 2001 Durex(R) Global Sex Survey Reveals That Americans are Having More Sex But Also Taking Risks: PRNewswire - November 27, 2001; ATLANTA, Nov. 27 /PRNewswire/ -- Americans are having sex more often, an average of 124 times per year, than people living anywhere else in the world according to this year s Global Sex Survey by Durex(R). And, the survey found that Americans have more partners, an average of 14.3, beating out the other world-leaders,
bioMerieux Receives PMA Approval for HIV-1 Viral Load Assay To Aid in Prognosis and Therapeutic Monitoring: PRNewswire - November 26, 2001; DURHAM, N.C., Nov. 26 /PRNewswire/ -- bioMerieux, Inc. has received Premarket Approval (PMA) from the United States Food and Drug Administration ( FDA ) for its NucliSens(R) HIV-1 QT quantitative viral load assay. Using the firm s proprietary Nucleic Acid Sequence-Based Amplification (NASBA) technology, the test identi
New Clinic to Offer Patient Tailored HIV Therapy; Minnesota Comprehensive Care Center Announces Grand Opening: PRNewswire - November 26, 2001; ROSEVILLE, Minn., Nov. 26 /PRNewswire/ -- Minnesota Comprehensive Care Center is celebrating its grand opening with an open house on Friday, November 30, from 3:00 p.m. to 7:00 p.m. Speakers include: Dr. Ron Falcon, Director, Minnesota Comprehensive Care Center and pioneer in patient tailored HIV therapy; Dr. Keith Hen
International AIDS Treatment Advocates Convene in Canada: Historic Conference Brings Together HIV/AIDS Treatment Experts From U.S., Canada, Mexico & Eastern Europe: PRNewswire - November 21, 2001; WASHINGTON, Nov. 21 /PRNewswire/ -- AIDS activists and workers from across North America will convene in Vancouver from December 2-5 for the 2001 North American AIDS Treatment Action Forum (NATAF). NATAF will bring together individuals from the United States , Canada , Mexico
WDI Receives Certification for Key Diagnostic Tests in Uganda -- Paves Way for Growth in Sales --: PRNewswire - November 20, 2001; MIAMI LAKES, Fla., Nov. 20 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI) (WDI), http://www.worlddiagnostics.com, a global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it has received certification for its rapid HIV,
Atrix Submits Investigational New Drug Application to Test Oral Interferon In HIV-Related Condition: PRNewswire - November 19, 2001; FORT COLLINS, Colo., Nov. 19 /PRNewswire/ -- Atrix Laboratories, Inc. (Nasdaq: ATRX) announced today that the company has submitted an Investigational New Drug application (INDA) to the U.S. Food and Drug Administration ( FDA ) to proceed into human clinical studies with a low dose oral interferon-alpha product for the
Endocrine Disorders Complicate Treatment for HIV Infection, Says American Association of Clinical Endocrinologists: PRNewswire - November 16, 2001; JACKSONVILLE, Fla., Nov. 16 /PRNewswire/ -- A new study, which may be found at http://www.aace.com/pub/ep/EP00111.pdf, indicates that a combination of chronic diseases is now a major problem in the treatment of many patients with HIV infection, and that some of these diseases are going untreated. A study entitled Syndr
ViroLogic Launches First Combination HIV Drug Resistance Test to Provide Phenotypic and Genotypic Information on a Single Report: PRNewswire - November 15, 2001; SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company has launched PhenoSense GT(TM), the first HIV drug resistance test to provide doctors with a single report on a patient s drug resistance profile using phenotypic test results supplemented by genotypic i
Progenics Awarded $1.2 Million for Development of Innovative HIV Therapies: PRNewswire - November 15, 2001; TARRYTOWN, N.Y., Nov. 15 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it had been awarded approximately $1.2 million from the National Institutes of Health (NIH) for the development of novel inhibitors of HIV (human immunodeficiency virus) entry and infection. Entry inhibitors are
PhRMA: WTO Doha Declaration Reaffirms Value of Intellectual Property Protection: PRNewswire - November 14, 2001; WASHINGTON, Nov. 14 /PRNewswire/ -- America s pharmaceutical industry recognizes the importance of the political statement reached in Doha that explicitly maintains TRIPS Agreement rights and obligations reaffirming that intellectual property protection promotes public health by encouraging the discovery and developmen
VaxGen to Present at Informed Investors Virtual Biotechnology Stocks Forum on Nov. 17: PRNewswire - November 14, 2001; BRISBANE, Calif., Nov. 14 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) will be among the companies featured during the Informed Investors Virtual Biotechnology Stocks Forum on Saturday, Nov. 17. Lance Ignon, VaxGen s vice president of corporate communications, will present a company overview and respond to questions vi
World Diagnostics, Inc. Opens New Office in Brazil: Registers WDI Products for Sale to Brazilian Government Agencies: PRNewswire - November 13, 2001; MIAMI LAKES, Fla., Nov. 13 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI), http://www.worlddiagnostics.com, an emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it has established an office of World Diagno
Genelabs Technologies, Inc. Reports Third Quarter and Nine Month 2001 Financial Results: PRNewswire - November 13, 2001; REDWOOD CITY, Calif., Nov. 13 /PRNewswire/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) today reported revenues of $1.1 million and a net loss of $3.0 million, or $0.06 per share, for the quarter ended September 30, 2001, compared with revenues of $1.6 million and a net loss of $2.7 million, or $0.06 per share, for th
BioMedicines Presents Promising Results from Phase II Trials Of Omega Interferon for the Treatment of Hepatitis C: PRNewswire - November 12, 2001; DALLAS, Nov. 12 /PRNewswire/ -- BioMedicines, Inc. today announced positive results from two Phase II clinical trials employing the company s omega interferon for the treatment of patients chronically infected with the hepatitis C virus (HCV). The results from clinical trials conducted at the Scripps Institute in the
Malaria Parasites Cleared in Patients With Hollis-Eden Pharmaceuticals Immune Regulating Hormone: Company Presents Clinical Trial Results At 50th American Society of Tropical Medicine and Hygiene: PRNewswire - November 12, 2001; SAN DIEGO, Nov. 12 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced preliminary results from a Phase II study treating Plasmodium falciparum malaria-infected patients in Thailand with the Company s lead investigational drug candidate, HE2000, an immune regulating hormone. Within the 7-d
Schering-Plough Reports Results of Clinical Studies of PEG-INTRON(TM) And REBETOL(R) Combination Therapy For Hepatitis C at American Association for the Study of Liver Diseases Meeting: Data Presented On Wide Variety Of Patient Populations: PRNewswire - November 12, 2001; DALLAS, Nov. 12 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported results of several clinical studies presented here at the 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on PEG-INTRON(TM) (peginterferon alfa-2b) Powder for Injection in combination with REBE
HUD Awards Nearly $200 Million to Florida: PRNewswire - November 9, 2001; WASHINGTON, Nov. 9 /PRNewswire/ -- Housing and Urban Development Secretary Mel Martinez today announced communities across Florida will receive nearly $200 million in federal assistance to stimulate local economies, promote affordable housing and help the homeless and persons living with AIDS. These grants do so much g
Statement by Alan F. Holmer, President of Pharmaceutical Research And Manufacturers of America, on the Opening of the World Trade Organization Ministerial on American Pharmaceutical Companies' Commitment To Better Access to New Medicines: PRNewswire - November 9, 2001; WASHINGTON, Nov. 9 /PRNewswire/ -- The following is a statement by Alan F. Holmer, President of Pharmaceutical Research and Manufacturers of America: At the occasion of the World Trade Organization (WTO) Ministerial in Doha, Qatar , leading American research-based pharmaceutical companies take this opportunity to reaff
Empire Health Resources Announces Failure to Consummate Strategic Alliance with Hemispherx Biopharma: PRNewswire - November 9, 2001; NEW YORK, Nov. 9 /PRNewswire/ -- Empire Medical Resources, Inc., a privately held healthcare management firm, announced today that it has never entered an agreement regarding a strategic partnership with Hemispherx Biopharma, Inc. (Amex: HEB), a biopharmaceutical company specializing in the development of nucleic acids
Hollis-Eden Pharmaceuticals Presents Anti-Inflammatory Effects Of Immune Regulating Hormones: PRNewswire - November 8, 2001; SAN DIEGO, Nov. 8 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced data from three separate presentations at the Cytokine Odyssey 2001 meeting held this week in Maui, Hawaii. The presentations include clinical results with the Company s lead immune regulating hormone, HE2000, indicating
Christians and Aids: Christians From Six Continents to Meet in Washington, D.C., February 17-21 for Prescription for Hope Conference on Response to the AIDS Pandemic: PRNewswire - November 7, 2001; BOONE, N.C., Nov. 7 /PRNewswire/ -- Seeking a coordinated response to the international HIV/AIDS crisis, Christians from six continents will meet in Washington, D.C. Feb. 17-21, 2002, for an international Christian conference on HIV/AIDS, called Prescription for Hope. The conference is sponsored by international relief
New Hepatitis C Research Reported at Major Medical Meeting; Thirteen Abstracts on PEGASYS(R) (peginterferon alfa-2a) to be Presented: PRNewswire - November 7, 2001; DALLAS, Nov. 7 /PRNewswire/ -- PEGASYS (peginterferon alfa-2a) -- Roche s once-weekly, pegylated form of interferon that is being investigated for the treatment of hepatitis C -- will be the subject of 13 oral presentations and poster sessions at The American Association for the Study of Liver Disease (AASLD) meeting i
amfAR Founding Chairman Dr. Mathilde Krim to Receive The Africa-America Institute's Individual Vision and Achievement Award: PRNewswire - November 7, 2001; NEW YORK, Nov. 7 /PRNewswire/ -- On Tuesday, November 13, Dr. Mathilde Krim, Founding Chairman and Chairman of the Board of the American Foundation for AIDS Research (amfAR), will receive the Africa-America Institute s Award for Individual Vision and Achievement in New York City. Dr. Krim, who is a Life Trustee of the
AnorMED announces AMD-3100 mobilizes stem cells: Study Results to be Presented at Upcoming American Society of Hematology:Meeting December 10th 2001, Orlando Florida: PRNewswire - November 7, 2001; VANCOUVER, BC, Nov. 7 /PRNewswire/ - AnorMED Inc. (TSE: AOM ) announced today that results from a Phase I study in healthy volunteers demonstrate that its drug candidate AMD-3100, a CXCR4 chemokine inhibitor, rapidly mobilizes hematopoietic progenitor cells (stem cells) which are the precursors of mature blood cells ou
Skaggs Design Teams Up With AIDS Project Los Angeles to Raise Funds And Awareness Over the Holiday Season: PRNewswire - November 6, 2001; SAN FRANCISCO, Nov. 6 /PRNewswire/ -- Since 1982, the Los Angeles AIDS Project has been at the heart of AIDS and HIV awareness, contributing millions of dollars to developing educational outreach programs and direct support services to men, women and children living with HIV and AIDS. To continue its role in raising aw
Schweiker Administration Adds Schizophrenia Drug To Pharmaceutical Benefits Program: Five Medications for Schizophrenia Now Covered: PRNewswire - November 6, 2001; HARRISBURG, Pa., Nov. 6 /PRNewswire/ -- On behalf of Pennsylvania Gov. Mark Schweiker, Department of Public Welfare (DPW) Secretary Feather O. Houstoun today announced the addition of Geodon (ziprasidone), an atypical anti-psychotic medication used to treat schizophrenia, to the state s Special Pharmaceutical Benefits
ViroLogic Announces Third Quarter 2001 Financial Results:Patient Testing Business Continues to Grow Steadily; Third Quarter Revenue Temporarily Affected by Tragic Events of September 11th and Variability Of Clinical Trial Timing: PRNewswire - November 6, 2001; SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the third quarter ended September 30, 2001. The Company reported revenue of $4.4 million for the quarter, an increase of 134 percent over revenue of $1.9 million for the same period in 2000. Third qua
NeoGenesis and Immusol Form HIV Drug Development Joint Venture: PRNewswire - November 6, 2001; SAN DIEGO and CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Immusol, Inc. and NeoGenesis Pharmaceuticals, Inc., a privately held biotechnology company, today announced that they will collaborate to discover small molecule drug candidates for the treatment of HIV. The agreement will bring together Immusol s well-established
Vical to Receive $3 Million Milestone Payment; Merck Advances HIV Vaccine Testing: PRNewswire - November 5, 2001; SAN DIEGO, Nov. 5 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL) announced today that it has received a $3-million payment from Merck & Co. , Inc. (NYSE: MRK), which has begun human testing of a prime-boost vaccine regimen that employs Vical s patented naked DNA non-viral gene delivery technology to combat human
Alexion Pharmaceuticals Acquires Worldwide Rights Related to Novel Immune System Targets - Monoclonal Antibodies Block Fundamental Human Immune System Components: PRNewswire - November 5, 2001; CHESHIRE, Conn., and NIJMEGEN, Netherlands , Nov. 5 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has acquired exclusive worldwide commercial rights related to newly discovered cell surface proteins, DC-SIGN, found exclusively on human dendritic cells and a related receptor, L-SIG
Viracept(R) Combination Therapy Demonstrates Durable Response Following Switch From An NNRTI-Based Regimen: Treatment Failure and Tolerability Cited Most Often as Reason for Switch from NNRTI -: PRNewswire - November 2, 2001; ATHENS, Greece , Nov. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. reported that VIRACEPT(R) (nelfinavir mesylate) provided a durable HIV viral load suppression, as well as an increase in CD4 cells, based on a multi-center, retrospective chart review of 234 patients living with HIV.
VIRACEPT(R) Combination Therapy Continues to Demonstrate Long Term Durability in Combating HIV After Four Years: PRNewswire - November 2, 2001; ATHENS, Greece , Nov. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. presented data from the long-term extension (LTE) phase of its pivotal study 511, examining immunologic reconstitution, efficacy and safety of VIRACEPT(R) (nelfinavir mesylate) in combination with
American Medical Laboratories Offers State-of-the-Art HIV Resistance Testing; Patient Care for HIV-Infected Individuals is Enhanced Significantly: PRNewswire - November 2, 2001; CHANTILLY, Va., Nov. 2 /PRNewswire/ -- American Medical Laboratories, Inc. (AML) announced today that it entered into an agreement with Virco Lab, Inc. of Rockville, MD to provide HIV Resistance Testing in addition to AML s HIV-1 Genotyping. AML will be able to offer clinicians Virco s VirtualPhenotype(TM) test and Vir
VaxGen to Present Progress Updates in Seattle, New York, and West Palm Beach, Nov. 5-7: PRNewswire - November 1, 2001; BRISBANE, Calif., Nov. 1 /PRNewswire/ -- Senior executives of VaxGen , Inc. (Nasdaq: VXGN) will present updates to the investment communities in Seattle, New York, and West Palm Beach, Fla., during the week of Nov. 5, 2001. Donald P. Francis, M.D., D.Sc., president, and Lance K. Gordon, Ph.D., chief executive officer,
Covering the West Hollywood Halloween Carnaval? Consider Dropping by 'Out' Boutique for Some B-Roll of the Bruce Willis Items: Last Minute Halloween Costume? Consider Bidding on a Leather Varsity Jacket, Other Clothing & Furnishings from Hollywood Actor Bruce Willis: PRNewswire - October 31, 2001; WEST HOLLYWOOD, Calif., Oct. 31 -- Clothing and personal items donated by Hollywood film star Bruce Willis to AIDS Healthcare Foundation (AHF) will be sold today Halloween night during a special holiday silent auction at AHF s Out (Out of The Closet store) at 8861 Santa Monica Boulevard in West Hollywood. The silent au
Once-Daily Zerit (stavudine) QD Capsules Safe and Effective: PRNewswire - October 31, 2001; ATHENS, Greece , Oct. 31 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection show that a new once-daily Zerit ( stavudine or
Twice-Daily HIV Regimen With FORTOVASE(R) and Mini-Dose Ritonavir Evaluated In Independent Clinical Studies - Less Frequent Dosing Offers Potential to Improve Adherence -: PRNewswire - October 31, 2001; ATHENS, Greece , Oct. 31 /PRNewswire/ -- New data were released today from two independently conducted clinical studies evaluating a twice-daily HIV treatment regimen of Roche s protease inhibitor FORTOVASE(R) in combination with mini-dose ritonavir .
Artists Against AIDS Worldwide's New Superstar Version of Marvin Gaye's 'What's Going On' In Stores Tuesday, October 30: Proceeds to Support AIDS Charities & Sept 11 Victims Relief Fund: PRNewswire - October 30, 2001; LOS ANGELES, Oct. 30 /PRNewswire/ -- Artists Against AIDS Worldwide s new, all-star version of Marvin Gaye s 1971 hit What s Going On, featuring Christina Aguilera, Backstreet Boys, Mary J. Blige, Bono, Destiny s Child, Sean P. Diddy Combs, Fred Durst (of Limp Bizkit), Nelly Furtado, Marvin Gaye III, Nona Gaye, Darren
Potential Once-Daily Anti-HIV Combination of SUSTIVA(R)+VIDEX(R)+FTC Demonstrates Strong Antiviral and Immunologic Effects in Pilot Study Through 96 Weeks: Pharmacokinetic Data from Study Support Once-Daily Dosing for This Regimen: PRNewswire - October 30, 2001; WILMINGTON, Del., Oct. 30 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece suggest that the once-daily protease inhibitor-sparing regimen of Bristol-Myers Squibb s (NYSE: BMY) SUSTIVA(R) (
Dr. Edmund Tramont, Director of the Division of AIDS at NIAID/NIH, Presents Significant Clinical Data With CEL-SCI Drug in HIV-Infected Women With Human Papilloma Virus (HPV) Induced Cervical Dysplasia: PRNewswire - October 30, 2001; VIENNA, Va., Oct. 30 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announced today the presentation of additional new clinical data for CEL-SCI s immunotherapy drug, Multikine(TM), at the 40th Annual ACOG (American College of Obstetricians and Gynecologists) Meeting of the Armed Forces District in Norfolk, Virginia.
VaxGen's AIDS Vaccine Clears 6th Safety Review; N. American/European Study Scheduled to Conclude in One Year: PRNewswire - October 29, 2001; BRISBANE, Calif., Oct. 29 /PRNewswire/ -- The independent board that oversees the world s only final-stage clinical trials of an AIDS vaccine has once again indicated that the vaccine appears safe and that the trials are being conducted appropriately, VaxGen , Inc. (Nasdaq: VXGN) announced today. In its sixth revie
Two Protease Inhibitor-Switch Studies Show Longer Virologic Response in Patients Switching to a Regimen Containing SUSTIVA(R): PRNewswire - October 29, 2001; WILMINGTON, Del., Oct. 29 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece show that patients who substituted Bristol-Myers Squibb s (NYSE: BMY) anti-HIV drug SUSTIVA(R) (
Atazanavir Demonstrates Antiviral Efficacy and a Favorable Lipid Profile at 48 Weeks: PRNewswire - October 29, 2001; ATHENS, Greece - Data shows that a regimen containing the novel and potent investigational protease inhibitor, atazanavir, given once daily as part of a highly active antiretroviral therapy (HAART) regimen is associated with significantly lower concentrations in total cholesterol, fasting LDL cholesterol and fasting tr
96-Week VIRAMUNE(R) (nevirapine) Study Results Presented At Major European AIDS Conference - Two Studies Examine Lipoprotein Profiles in Patients Taking VIRAMUNE: Boehringer Ingelheim Pharmaceuticals, Inc.; ATHENS, Greece , - Findings from two studies presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection demonstrate that HIV-positive individuals taking a VIRAMUNE(R) ( nevirapine )-based anti-HIV treatment combination were observed to have
International Organizations Join in Unprecedented Collaboration to Assist Africa's Children Orphaned by AIDS: PRnewswire - October 29, 2001; WASHINGTON and SEATTLE, Oct. 29 /PRNewswire/ -- Five leading international humanitarian organizations today announced they have joined to launch the Hope for African Children Initiative, an unprecedented collaboration that will address the enormous challenges faced by children whose lives have been devastated by the AI
Data Suggest SUSTIVA(R) May Have Greater Potency and Durability Than Viramune(R) in HIV Positive Treatment-Naive Patients: PRnewswire - October 29, 2001; WILMINGTON, Del., - Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece suggest that a regimen containing Bristol-Myers Squibb s (NYSE: BMY) anti-HIV drug SUSTIVA(R) ( efa
TMC125 Demonstrates Strong Antiviral Effect in HIV; First Clinical Results In Short-Term Study Are Promising: PRnewswire - October 29, 2001; ATHENS, Greece , - Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH) demonstrate an average reduction in the amount of HIV in patients plasma (viral load) of 99% after one week of treatment using Tibotec-Virco s novel, new candidate drug TMC125, a potent non
Simplification of HIV Treatment Schedules: Study Examines Once-Daily FORTOVASE(R) in Co-Infected Patients With HIV And Hepatitis C Receiving Methadone: Second Study Explores Changes in Drug Costs for 15 Patients Who Switched To Once-Daily FORTOVASE: PRNewswire - October 29, 2001; SAN FRANCISCO, Oct. 29 /PRNewswire/ -- Data from a retrospective review of patients co-infected with HIV and hepatitis C virus (HCV) receiving methadone indicate that a once-daily dose of Roche s protease inhibitor, FORTOVASE(R) ( saquinavir ), in combination wi
U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread(TM): PRNewswie - October 29, 2001; FOSTER CITY, Calif., Oct. 29 /PRNewswire/ -- Gilead Sciences (Nasdaq: GILD) announced that it received U.S. Food and Drug Administration ( FDA ) approval on Friday, October 26, for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of
VA Establishes New Hepatitis C and HIV Field Office: PRnewswire - October 26, 2001; WASHINGTON, Oct. 26 /PRNewswire/ -- To better address the needs of nearly 100,000 veterans infected with hepatitis C or HIV, the Department of Veterans Affairs (VA) recently established a new field office in West Haven, Conn., that will provide front-line perspective to the national program. Dr. Michael Rigsby, an
New Strategy Doubles Efficacy of Hepatitis C Treatment In Patients Co-infected with HIV: Co-infection a Focus at Infectious Diseases Society of America Annual Meeting: PRNewswire - October 26, 2001; SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Daily administration of interferon alfa-2b in combination with ribavirin for the treatment of the hepatitis C virus (HCV) is more than twice as effective as the standard treatment regimen (three injections interferon/week plus ribavirin) at suppressing hepatitis C viral levels in
Trinity Medical Group USA Announces Publication of REMUNE(R) Study Results at 132 Weeks: PRNewswire - October 26, 2001; RANCHO SANTA MARGARITA, Calif., Oct. 26 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announces the publication of follow-up results of a human clinical study of an Immune-Based Therapy for the treatment of HIV, REMUNE(R), at 5 sites in Thailand . The study results, together with pre
Progenics Enters Collaboration With Formatech to Develop Improved Dosing Formulations For Investigational HIV Drug Pro 542- Collaboration Leverages New Efficacy Data in HIV Animal Model: PRNewswire - October 26, 2001; SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the initiation of a collaboration with Formatech, Inc., Andover, MA, to develop improved product formulations for PRO 542, an investigational drug currently in Phase II clinical testing for the treatment of HIV (human immuno
Visible Genetics' TRUGENE(TM) HIV-1 Genotyping Kit To Be Used in a GlaxoSmithKline Sponsored Clinical Trial: PRNewswire - October 25, 2001; TORONTO, Oct. 25 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) ( VGI ) announced today that Visible Genetics TRUGENE(TM) HIV-1 Genotyping Kit will be used to provide genotypic information on all patients enrolled in a large-scale Phase III clinical trial sponsored by GlaxoSmithKline (NYSE: GSK) for a new HIV
The Month-Long 102.9 WMGK Rock Art Show and Silent Auction Opens to the Public On Friday, November 16 and Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - October 24, 2001; PHILADELPHIA, Oct. 24 /PRNewswire/ -- WMGK (102.9FM/Philadelphia) will showcase a never-before-seen collection of original art and lithographs, as well as handwritten, autographed song lyrics from popular music s greatest songwriters at the second annual 102.9 WMGK Rock Art Show to benefit the Elizabeth Glaser Pediatri
FDA Approves Investigational Device Exemption For Efoora HIV Rapid Test: PRNewswire - October 24, 2001; BUFFALO GROVE, Ill., Oct. 24 /PRNewswire/ -- Efoora, Inc. announced today that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food & Drug Administration has granted an Investigational Device Exemption (IDE) for Efoora s HIV Rapid Test. The IDE will allow the Efoora HIV Rapid test to be used in
Bio-Rad Grants HIV-2 License to Genelabs Diagnostics: Settlement Agreement Allows Continued Sales of Confirmatory HIV Tests: PRNewswire - October 24, 2001; HERCULES, Calif., and SINGAPORE, Oct. 24 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (Amex: BIO.A and BIO.B) and Genelabs Diagnostics Pte. Ltd. announced today that they have reached an agreement that allows Genelabs Diagnostics to continue to manufacture and sell the company s HIV-2 Western Blot 1.2 and HIV Blot 2.2 We
National Institute of Health Utilizes Bioject'S Needle-Free Injection System For Its DNA AIDS Vaccine Study: The First Volunteer of a Planned 20 Patient Cohort Injected: PRNewswire - October 23, 2001; PORTLAND, Ore., Oct. 23 /PRNewswire/ -- Bioject Medical Technologies, Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, today announced that the Biojector(R) 2000 (B-2000) is the delivery device being used by the Dale and Betty Bumpers Vaccine Research Center (VRC) for the human clinical te
Phase I Clinical Trial to Commence on SLIL Cancer Drug, SL11047: PRNewswire - October 23, 2001; MADISON, Wis., Oct. 23 /PRNewswire/ -- SLIL Biomedical Corp. announced that the FDA has completed its review of the Investigational New Drug application (IND) for SLIL s candidate drug, SL11047. Phase I human clinical trials with the drug will now commence. The Phase I clinical study, aimed at AIDS-
The National AIDS Treatment Advocacy Project Announces 'A Day For Women': PRNewswire - October 22, 2001; NEW YORK, Oct. 22 /PRNewswire/ -- HIV is a growing problem for women in the United States . Infection rates among women continue to steadily increase. Among women of color, the rate of new infections is disproportionately increasing compared to other groups. HIV treatment and care is different for women than it is for
Walkers Raise $2.5 Million at AIDS Walk Los Angeles, Sunday, October 21: PRNewswire - October 21, 2001; LOS ANGELES, Oct. 21 /PRNewswire/ -- More than 20,000 people turned out for AIDS Walk Los Angeles on Sunday, October 21. Together, they raised $2.5 million in a showing of this community s continued and determined support for the work of APLA, according to Craig Miller, the event s long time producer. Mayor James Hahn,
VaxGen Obtains Land in South Korea for Manufacturing Facility: PRNewswire - October 19, 2001; BRISBANE, Calif., Oct. 19 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) and the city of Incheon, South Korea , announced the signing of an agreement today that provides VaxGen land on which to construct a facility to manufacture the company s AIDS vaccine. This agreement is the first step in VaxGen s program to
Oxfam Lauds U.S. Effort in Making Anti-Anthrax Medicine Available: PRNewswire - October 17, 2001; WASHINGTON, Oct. 17 /PRNewswire/ -- Oxfam America is lauding recent efforts by the U.S. Government to provide a much-needed antibiotic. The Government is asking Bayer Corporation to relax its patent on the anti-anthrax medicine, Cipro (ciprofloxacin). Oxfam America s Senior Policy Adviser, Severina Rivera, praised the
ViroLogic Announces Broadened Agreement With Roche and Trimeris for Use of Its HIV Drug Resistance Testing Technology: PRNewswire - October 16, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire/ -- ViroLogic, Inc. today announced that the Company signed an expanded agreement with Hoffmann-La Roche , Inc. and Trimeris, Inc. to use ViroLogic s proprietary HIV resistance testing technology in the development of T-20 and T-1249, the first and most advanced members
Mixed 2001 Legislative Session Frustrates AIDS Activists; AIDS Project Los Angeles Plans Aggressive Strategy for Future: PRNewswire - October 15, 2001; LOS ANGELES, Oct. 15 /PRNewswire/ -- Activists are stunned by a legislative session that saw fewer than expected advances in the area of HIV/ AIDS policy and diminishing support from Governor Gray Davis for prevention and education efforts. Despite his previous record, this year Governor Davis became the first Californ
Roche Molecular Systems International Blood Screening Business News: French Health Ministry and Japanese Red Cross Select Roche PCR Technology: PRNewswire - October 13, 2001; PLEASANTON, Calif., Oct. 13/PRNewswire/ -- Roche Diagnostics announced today that it was recently awarded substantial blood-screening business in France and Japan to screen the blood supply and to help prevent the transfusion of blood infected with certain viruses. FRENCH HEALTH MINISTRY AWARDS BLOOD SCREENING CONT
California Governor Acts on Two AHF-Sponsored Bills to Advance HIV Care: PRNewswire - October 12, 2001; LOS ANGELES, Oct. 12 /PRNewswire/ -- Two AIDS Healthcare Foundation (AHF) sponsored bills aimed at improving access to HIV/AIDS care for California managed care plan enrollees were acted on yesterday by California Governor Gray Davis. Assembly Bill 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) -- a bill to ensu
ViroLogic Announces Nearly All State Medicaid Programs Now Cover Its HIV Drug Resistance Assays: Company Plans to Launch Novel Resistance Assay Later This Year: PRNewswire - October 12, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- ViroLogic, Inc. today announced that 44 out of 50 U.S. state Medicaid programs, including California, New York, Illinois and Pennsylvania, now have coverage policies enabling reimbursement of the company s PhenoSense(TM) and GeneSeq(TM) HIV drug resistance assays. At
Decision Resources Report Forecasts Substantial Market Opportunities for Therapies to Treat Hepatitis B and C Viruses: PRNewswire - October 11, 2001; WALTHAM, Mass., Oct. 11 /PRNewswire/ -- The Prevention and Treatment of Select Viral Infections is a forthcoming DR Report from Decision Resources that evaluates the current and future status of therapeutic and prophylactic drugs and vaccines in development for six major viruses: human immunodeficiency virus (HIV),
Bruce Brochtrup, Wilson Cruz, Eric McCormack and Ming-Na to Host AIDS Walk Los Angeles Sunday, October 21: PRNewswire - October 11, 2001; New Post-Walk Entertainment Featuring Singer Songwriter From Ally McBeal, Vonda Shepard! New Location! New Route! AIDS Walk Begins at the Pacific Design Center in West Hollywood Proceeds Benefit AIDS Project Los Angeles and Other AIDS Service Organizations Across LA County LOS ANGELES, Oct. 11 /PRNewswire/ -- Thousands
PowderJect Awarded $1 Million U.S. Government Funding to Support Development of HIV DNA Vaccine: PRNewswire - Ocotber 11, 2001; OXFORD, England and MADISON, Wis., Oct. 11 /PRNewswire/ -- PowderJect Pharmaceuticals Plc (London: PJP), the rapidly growing specialty vaccines company, and its wholly owned subsidiary PowderJect Vaccines Inc, today announced that in association with the University of Pittsburgh the company has been awarded $1 million
Fundraiser Goes to the Net: Denver Chapter of Cable Positive Uses Internet To Expand Charity Efforts: Via the Web, People Can Get Event Information, Bid on Silent Auction Items And Get a Copy of the Words to All the Event's Song Parodies: PRNewswire - October 10, 2001; DENVER, Oct. 10 /PRNewswire/ -- The Denver chapter of Cable Positive has turned to the Internet to spread the word about its upcoming musical parody and raise funds to assist those infected with HIV and AIDS. The chapter has unveiled a temporary Web presence that provides an opportunity to bid in a Silent Auction, buy
amfAR Symposium to Focus on Women and HIV/AIDS: HIV Infection Now the Fifth Leading Cause of Death for Women in the United States: PRNewswire - October 10, 2001; NEW YORK, Oct. 10 /PRNewswire/ -- Women now account for more than 25 percent of AIDS cases in the United States , a percentage that has tripled since the epidemic first began 20 years ago. To help address this alarming situation, the American Foundation for AIDS Research (amfAR) will host a day-long medical symposium e
Cambridge Antibody Technology Announces Product Development Alliance With Merck & Co., Inc.: Collaborative program to develop novel drugs for the prevention and treatment of HIV-mediated infectious disease: PRNewswire - October 10, 2001; MELBOURN, England, Oct. 10 /PRNewswire/ -- Cambridge Antibody Technology announces today that it has entered into a collaboration and license agreement with Merck & Co. , Inc. for the research and development of products specific for a key target involved in disease mediated by HIV. Under the terms of the five-y
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs: PRNewswire - October 9, 2001; LOS ANGELES, Oct. 9 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork for AIDS Project Los Angeles (APLA) 2001 holiday card campaign. Created through a partnership with Soolip Paperie & Press, the holiday ca
European Humanitarian Group Orders Rapid HIV Tests From BICO Subsidiary - Rapid HIV Detection Corporation: PRNewswire - October 9, 2001; PITTSBURGH, Oct. 9 /PRNewswire/ -- The world appears to be gravitating toward Pittsburgh-based BICO, Inc. and their subsidiary, Rapid HIV Detection Corp. One week after Walter Reed Army Institute of Research placed their second order of InstantScreen(TM) Rapid HIV tests, an order for 1,000 tests has come from a Europea
Multikine(TM) Demonstrates Excellent Clinical Responses in HIV-Infected Women With Human Papilloma Virus (HPV) Induced Cervical Dysplasia: PRNewswire - October 9, 2001; * Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. * Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Virology and CEL-SCI suggests a potentially effective new trea
ViroLogic to Present at UBS Warburg LLC Global Life Sciences Conference Next Week in New York: PRNewswire - October 4, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire/ -- ViroLogic, Inc. announced today that the company will present at the UBS Warburg Global Life Sciences Conference on Friday, October 12, 2001 at 8:00 a.m. EDT. Bill Young, ViroLogic s chairman and chief executive officer will update members of the investment community
Regent Group, Inc. Announces That Co-discoverer of AIDS Virus Joins Research Consultant Team: PRNewswire - October 4, 2001; BERNARDSVILLE, N.J., Oct. 4 /PRNewswire/ -- Regent Group, Inc. announced today that Dr. Luc Montagnier, the world renowned virologist and co-discoverer of the virus that causes AIDS, has joined the research team of Millennium Biotechnologies, Inc., its wholly owned subsidiary. Dr. Montagnier will be responsible for ove
Visible Genetics' to Present at UBS Warburg LLC Global Life Sciences Conference: VGI Also Presenting at European Investor Conference: PRNewswire - October 4, 2001; TORONTO, Oct. 4 /PRNewswire/ -- Visible Genetics Inc. (VGI) announced today that Richard T. Daly, President and CEO of Visible Genetics will be presenting at the UBS Warburg Global Healthcare Conference being held next week in New York from October 8 to 12. Mr. Daly will give his presentation at 2:20 PM on Wednesday Oc
TherImmune Awarded $4.5 M for HIV Vaccine Development Services: PRNewswire - October 4, 2001; GAITHERSBURG, Md., Oct. 4 /PRNewswire/ -- TherImmune Research Corporation is pleased to announce its recent award of a 3-year $4.5 M HIV Vaccine Development Task Order awarded under their National Institute of Allergy and Infectious Diseases (NIAID) Indefinite Delivery - Indefinite Quantity Contract (IDIQ). The company
Scott Evertz, Director of the White House Office of National AIDS Policy, To Kick Off 11th Annual AIDS Arms LifeWalk in Dallas: PRNewswire - October 4, 2001; DALLAS, Oct. 4 /PRNewswire/ -- AIDS Arms, Inc., a Dallas-based agency providing both outpatient medical care and psychosocial services for persons diagnosed with HIV/AIDS, announced today that Scott Evertz, director of the White House Office of National AIDS policy, will kick off the eleventh annual AIDS Arms LifeWalk
Hollis-Eden Pharmaceuticals Cleared to Initiate Clinical Trial in Hepatitis B; The Company Initiates Dosing HE2000 in Malaria Patients: PRNewswire - October 4, 2001; SAN DIEGO, Oct. 4 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced that it has received approval to initiate a Phase II clinical trial in Hepatitis B (HBV) infected patients with the Company s lead investigational drug, HE2000, at Mt. Elizabeth Medical Centre in Singapore .
Myriad Genetics and University of Utah Publish Pioneering HIV Research in the Scientific Journal CELL: Scientists Identify Promising New Targets for HIV Drug Intervention: PRNewswire - Thursday October 4, 2001; SALT LAKE CITY, Oct. 4 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) and the University of Utah today announced the publication of the results of pioneering research into molecular mechanisms essential for the lifecycle of the Human Immunodeficiency Virus, (HIV) the virus known to cause AIDS (Acquired Imm
Virco Signs Major HIV Resistance Testing Contracts With Pharmaceutical Companies: Contracts Confirm Virco as Partner of Choice for Development of New HIV Drugs: PRNewswire - October 4, 2001; MECHELEN, Belgium , Oct. 4 /PRNewswire/ -- Virco announced today that it has entered into a number of agreements to provide HIV drug resistance testing and other analytical services to pharmaceutical companies. The contracts, with a number of leading pharmaceutical companies including Dupont Pharmaceuticals, are the la
5,300 Signatures in Support of AIDS Bill Delivered to Governor: AB 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) Strongly Supported in San Francisco Chronicle Editorial Today: PRNewswire - October 3, 2001; LOS ANGELES, Oct. 3 /PRNewswire/ -- 5,300 signatures in support of Assembly Bill 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) -- a bill that would help ensure access to HIV specialists for California HMO members living with HIV/AIDS -- were delivered to Governor Gray Davis office yesterday. The signatures are
Maxygen Awarded $3.7 Million USAID Cooperative Grant to Develop Malaria Vaccine: PRNewswire - October 3, 2001; REDWOOD CITY, Calif., Oct. 3 /PRNewswire/ -- Maxygen, Inc. announced today that it had received a $3.7 million, three-year grant from the U.S. Agency for International Development (USAID) to support the research and development of a novel, broadly protective malaria vaccine. Under the terms of the agreement, Maxygen wi
VaxGen Awarded Second NIH Grant for Development of AIDS Vaccine for Africa, India and China: PRNewswire - October 3, 2001; BRISBANE, Calif., Oct. 3 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that it has been awarded the second part of a $1.1 million grant from the National Institutes of Health (NIH) to continue the development of a vaccine designed to prevent infection by HIV subtype C, the most widespread form of the vir
Visible Genetics Acquires Former Virco UK Laboratory: VGI Establishes Major Research Facility In Europe: PRNewswire - October 3, 2001; TORONTO, Oct. 3 /PRNewswire/ -- Visible Genetics Inc. today announced that it has acquired Virco s international research laboratory in Cambridge, UK together with substantially all the research staff of about 25 scientists. VGI will acquire the laboratory assets for US$829,000 and assume the lease for the 20,000 squar
Web's Premier HIV/AIDS Resource Launches Prescription Program Serving People With HIV: A Contrast With New Glaxo Prescription Drug Program: PRNewswire - October 3, 2001; NEW YORK, Oct. 3 /PRNewswire/ -- TheBody.com today launched BodyPlus, a new online prescription drug program for people with HIV. The program will provide significant discounts and embarrassment-free delivery, and envisions an unprecedented level of highly targeted patient education by using the company s award-winning
Tibotec-Virco Reorganizes HIV Diagnostics; Transfer of Activities to Belgium to Improve Effectiveness: PRNewswire - October 3, 2001; MECHELEN, Belgium , Oct. 3 /PRNewswire/ -- Following the recent announcement to re-focus core activities geographically, Tibotec-Virco today announced that it has relocated its HIV genotyping services and HIV diagnostics research from Cambridge, UK to the company s headquarters in Mechelen, Belgium. We are delight
Churches Gearing Up for 13th Annual Black Church Week of Prayer for the Healing of AIDS: PRNewswire - October 2, 2001; NEW YORK, Oct. 2 /PRNewswire/ -- Churches across the country are gearing up for the 13th annual Black Church Week of Prayer for the Healing of AIDS March 3-9, 2002. The week, organized by The Balm In Gilead, is a national campaign, which mobilizes Black churches to become centers for AIDS education and compassion. Sinc
Epimmune Provides Cancer Vaccine Program Update: PRNewsire - October 2, 2001; SAN DIEGO, Oct. 2 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) today provided additional information on its cancer vaccine program including its initial vaccine candidate and clinical trial plans. Epimmune will move forward with a therapeutic lung cancer vaccine candidate and anticipates that it will file an Investigat
Amarillo Biosciences, Inc. Licenses Rights to Low Dose Oral Interferon For Orphan Drug Indications: PRNewsire - October 2, 2001; AMARILLO, Texas, Oct. 2 /PRNewswire/ -- Amarillo Biosciences, Inc. announces the company has signed a licensing agreement with Atrix Laboratories, Inc. (Nasdaq: ATRX) providing the rights to oral low-dose interferon-alpha for the treatment of Behcet s disease and oral papillomavirus warts in HIV-positive patients. The
BICO Receives Additional Order From Walter Reed For Rapid HIV Tests: PRNewswire - October 2, 2001; PITTSBURGH, Oct. 2 /PRNewswire/ -- BICO, Incorporated announced today that subsidiary Rapid HIV Detection Corp. has received an order for an additional 1,200 of its InstantScreen(R) Rapid HIV tests from Walter Reed Army Institute of Research in Washington, DC for use in scientific evaluation. In August, Walter Reed Ins
Final Preparations Made for AIDS Walk Michigan - City of Detroit; Record Numbers Anticipated for This Year's Walk: PRNewswire - September 28, 2001; DETROIT, Sept. 28 /PRNewswire/ -- Tomorrow morning the AIDS Memorial Quilt, on loan from its home in Atlanta, Georgia is unveiled at the Belle Isle Casino as part of AIDS Walk Michigan -- City of Detroit. The Quilt includes more than 30 quilt blocks that will be unpacked and put on display early in the morning in prepa
AIDS Walk Detroit Raises $340,000, Sets Records: 2001 Walk united and benefited many in Metro-Detroit: PRNewswire - September 28, 2001; ROYAL OAK, Mich., Sept. 28 /PRNewswire/ -- An estimated 16,000 people showed their American spirit on September 16 by raising a record $340,000 to help Metro-Detroiters whose lives have been affected by HIV and AIDS. The amount raised exceeded last year s record by more than $20,000 and brought the total raised by Step
VA Establishes New HIV Center: PRNewswire - September 28, 2001; WASHINGTON, Sept. 28 /PRNewswire/ -- In its continuing efforts to provide care to more than 20,000 veterans infected with HIV (Human Immunodeficiency Virus), the Department of Veterans Affairs (VA) has announced the creation of the Center of HIV Research Resources located at the Palo Alto Health Care System in Californ
FDA Grants Market Clearance of Visible Genetics' HIV Genotyping System: TRUGENE(TM) HIV-1 Genotyping Kit is First FDA Cleared DNA Sequence-Based Test For HIV Drug Resistance Testing: PRNewswire - September 26, 2001; TORONTO, Sept. 26 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) (VGI) today received clearance from the U.S. Food and Drug Administration ( FDA ) to market its TRUGENE(TM) HIV-1 Genotyping Kit and OpenGene(TM) DNA Sequencing System for routine clinical use, becoming the first HIV drug resistance test to receive
AHF Inducts PacifiCare Into their AIDS Hall of Shame: California Managed Care Plan Cited for Failure to Refer Patients to AIDS Specialists & Pay for AIDS Care, Leading Opposition to Legislation That Would Improve Care for Californians Living with HIV/AIDS: Gov. Davis Urged to Sign AB 937 (Koretz, D, W. Hollywood) to Improve Access To AIDS Care: PRNewswire - September 26, 2001; LOS ANGELES, Sept. 26 /PRNewswire/ -- In a press conference today in front of AIDS Healthcare Foundation s (AHF s) administrative offices, AIDS medical providers and activists inducted PacifiCare of California into the AIDS Hall of Shame for their ongoing mismanagement of HIV/AIDS patients HMO specialty care and referr
New Study Proves - Ameda HygieniKit Protects Breast Milk From Bacteria and Viruses*: PRNewswire - September 26, 2001; LIBERTYVILLE, Ill., Sept. 26 /PRNewswire/ -- There is good news for mothers who rely on electric breast pumps to provide breast milk to their babies. The Food and Drug Administration ( FDA ) reviewed and cleared the claim that the patented silicone diaphragm used in the Ameda HygieniKit milk collection system creates a
amfAR's Founding Chairman Dr. Mathilde Krim to Receive Eleanor Roosevelt Val-Kill Medal: PRNewswire - September 26, 2001; NEW YORK, Sept. 26 /PRNewswire/ -- On Sunday, September 30, Dr. Mathilde Krim, Founding Chairman and Chairman of the Board of the American Foundation for AIDS Research (amfAR), will receive the Eleanor Roosevelt Val-Kill Medal in recognition of her leadership role in galvanizing the nation s research effort against HIV
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: PRNewswire - September 25, 2001; Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs LOS ANGELES, Sept. 25 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork fo
20 Years, 22 Million Lives Lost to AIDS: Register Now to Walk, Run and Stroll in 15th Annual AIDSWalkPhilly2001 on Sunday, October 21: PRNewswire - September 25, 2001; PHILADELPHIA, Sept. 25 /PRNewswire/ -- 20 years after doctors reported that a strange and deadly new disease turned up in five gay men in Los Angeles, more than 22 million people worldwide have lost their lives to AIDS and that number increases daily. Area residents are encouraged to register to walk, run or stroll in
Conference to Explore Inextricable Connection Between Health, Law and Human Rights: PrNewswire - September 24, 2001; NEW YORK, Sept. 24 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) will sponsor a conference entitled Health, Law and Human Rights: Exploring the Connections from September 29 to October 1, 2001, in Philadelphia. Conference participants from around the world will discuss the use of law and human right
Prominent Physician Named Head of New South African AIDS Clinic; Ithembalabantu 'People's Hope' Clinic to Provide Antiretroviral Treatment: PRNewswire - September 24, 2001; LOS ANGELES, Sept. 24 /PRNewswire/ -- South Africa s newest HIV clinic, a joint effort between American and South African AIDS activists, will be headed by a South African physician with extensive experience in HIV/AIDS treatment. Dr. Lerato Mohapi, MBBCH, will oversee the treatment program as Medical Director of the I
CEL-SCI Corporation Announces Clinical Data To Be Presented in October at the Annual Meeting Of The International Society for Interferon and Cytokine Research: PRNewswire - September 24, 2001; Clinical Study of HIV-Infected Women With Human Papilloma Virus ( HPV ) Induced Cervical Dysplasia, the Precursor Stage Before the Development of Cervical Cancer. Dysplasia Is Usually Detected Through Pap Smear. Cervical Cancer Is The Second Leading Cause of Cancer Death in
LabCorp's National Genetics Institute Receives FDA Approval for Nucleic Acid Tests for HCV and HIV-1: PRNewswire - September 21, 2001; BURLINGTON, N.C., Sept. 21 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that its National Genetics Institute Inc. (NGI) had its Biologics License Applications for the UltraQual(TM) HCV RT-PCR and UltraQual(TM) HIV-1 RT-PCR assays approved by the U. S. Food and Dr
ViroLogic Enters Agreement With Triangle Pharmaceuticals to Evaluate New HIV Drugs - PhenoSense(TM) Technology to Assess HIV Susceptibility To Investigational Compounds: PRNewswire - September 20, 2001; SOUTH SAN FRANCISCO, Calif., Sept. 20 /PRNewswire/ -- ViroLogic Inc. (Nasdaq: VLGC) today announced an agreement with Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS), to assist in clinical evaluation of new anti-HIV agents in development at Triangle Pharmaceuticals. Triangle Pharmaceuticals will use ViroLogic s phenotypi
Myriad Genetics Reports Advanced Pre-Clinical Progress With Anti-HIV Drug - IND Filing for Human Clinical Trials Expected This Fiscal Year: PRNewswire - September 20, 2001; SALT LAKE CITY, Sept. 20 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today reported pre-clinical data on its lead Anti-HIV compound, MPI-49839. The drug addresses a novel mechanism in the viral-host interaction and holds the potential for an entirely new class of AIDS therapeutics. In pre-clinical tests, MPI-
Name Change Announced for Female Condom Product: PRNewswire - September 19, 2001; CHICAGO, Sept. 19 /PRNewswire/ -- The Female Health Company announced today the establishment of FC Female Condom(R) as the Company s worldwide trademark for its female condom. The Company has previously sold the female condom as REALITY to consumers in the US. According to the Company s President, Dr. Mary Ann Leeper,
CEL-SCI Corporation Announces Issuance of Three New U.S. Patents Covering HIV Immunotherapeutic Agents: PRNewswire - September 19, 2001; VIENNA, Va., Sept. 19 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announced today the issuance of three new U.S. patents, further expanding the patent protection related to its HIV-1 based therapeutic and preventive vaccines. These new patents expand the Company s intellectual property protection to the C strain (c
Want to Give Blood? First See If You Are Eligible Suggests the American Society of Clinical Pathologists: PRNewswire - September 18, 2001; CHICAGO, Sept. 18 /PRNewswire/ -- The American Society of Clinical Pathologists (ASCP) is urging potential blood donors to review their personal medical history and other factors before heading to the nearest blood collection center. Due to the overwhelming response, many collection centers are filled with potential do
Midwest AIDS Prevention Project: 'ARTWORKS FOR LIFE' Benefit, Saturday, September 22; A Portion of the Proceeds to Benefit the Red Cross: Detroit Artists Unite in the Fight Against AIDS: PRNewswire - September 18, 2001; FERNDALE, Mich., Sept. 18 /PRNewswire/ -- Over 150 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the sixth annual ARTWORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 22, 2001 and will be held at the Edsel and Eleanor Ford House in Grosse Poin
From Ashes of Despair, a Ray of Hope and Determination from AIDS Community; 300+ Travel By Car, Train, Bus to Nation's Largest Conference in Show Of Compassion and Empathy for Those Impacted By Tragedy: PRNewswire - September 14, 2001; MIAMI BEACH, Fla., Sept. 14 /PRNewswire/ -- They came from as far away as Kenya and Micronesia , arriving in Miami Beach before this week s horrible tragedy. They drove, took the train and the bus from as far away as California when their flights were cancelled. They are the more than 300 people fighting the
Real People. Real Stories. AIDS Walk Detroit; Redford Man Lost His Wife To AIDS - Walks So No One Else 'Loses Their Lori': PRNewswire - September 12, 2001; ROYAL OAK, Mich., Sept. 12 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Ken, of Redford, whose
New York Baby AIDS Law Continues to Show Great Success; All HIV-Exposed Babies Identified, 99.4% Receiving Medical Care: PRNewswire - September 11, 2001; ALBANY, N.Y., Sept. 11 /PRNewswire/ -- Rates of perinatal HIV transmission continue to drop in New York and nearly all HIV exposed babies born in the state are receiving medical care, according to new data from the New York State Department of Health AIDS Institute. One in ten HIV-positive pregnant women, however, only
IGEN Presents Four New High-Throughput Screening Tests: Integrase Test Successfully Accelerated Screening for Potential New AIDS Drugs: PRNewswire - September 11, 2001; GAITHERSBURG, Md., Sept. 11 /PRNewswire/ -- Scientists from IGEN International Inc. (Nasdaq: IGEN) are this week presenting recent research results from four new screening tests developed by IGEN to speed the discovery of new drugs. The presentations being made at the annual meeting of the Society for Biomolecular Scre
Hollis-Eden Presents Data Demonstrating HE2000 Regulates a Broad Array of Inflammatory Mediators Implicated in Disease Progression in HIV Patients: Findings Also Have Implications for Other Inflammatory Conditions: PRNewswire - September 10, 2001; SAN DIEGO, Sept. 10 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced presentation of additional clinical results from its South African studies of investigational drug candidate HE2000, an immune regulating hormone (IRH). Highlights from the results demonstrate that HE2000 administered t
Santana Band Co-Founder Gregg Rolie to Perform Santana Classics at Macy's And American Express Passport '01 Fundraisers in Los Angeles and San Francisco Benefitting HIV/AIDS Charities: PRNewswire - September 7, 2001; SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Rock n Roll Hall of Famer and veteran keyboardist-vocalist-producer Gregg Rolie, co-founder of multi- platinum acts Santana and Journey, will perform at the Macy s and American Express Passport 01 galas in San Francisco (Fort Mason Center, September 12-13-14) and Los Angeles (Sant
Global Reporting Initiative Receives Nearly $1 Million From Bill and Melinda Gates Foundation for HIV Work: Grant Awarded to Develop Corporate HIV/AIDS Reporting Protocol: PRNewswire - September 7, 2001; BOSTON, Sept. 7 /PRNewswire/ -- The Global Reporting Initiative (GRI) announced today that it has received a $950,000 grant from the Bill and Melinda Gates Foundation to develop a corporate HIV/AIDS reporting protocol. The grant, which will be administered by the Coalition for Environmentally Responsible Economies (CER
Epimmune Provides HIV Vaccine Program Update: PRNewswire - September 7, 2001; SAN DIEGO, Sept. 7 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN), presenting at the AIDS Vaccine 2001 Conference in Philadelphia today, provided additional information on its HIV vaccine program including its initial vaccine candidate and clinical trial plans. Epimmune anticipates that it will file an Investigational Ne
CEL-SCI Corporation Reports Promising Preclinical Results With Potential HIV Immunotherapeutic Agent: PRNewswire - September 7, 2001; VIENNA, Va., Sept. 7 /PRNewswire/ -- CEL-SCI Corporation (Amex: CVM) announces today s presentation of a poster at the AIDS Vaccine 2001 Congress in Philadelphia, PA entitled C Clade HGP-30 {p17 aa 86-115} Based Peptide Conjugates as Potential Therapeutic and Prophylactic HIV-1 Vaccine Antigens. In it, strong evidence
Real People. Real Stories. AIDS Walk Detroit; Birmingham Teacher Walks For the Future of His Students: PRNewswire - September 7, 2001; ROYAL OAK, Mich., Sept. 7 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Jerry, a Birmingham educ
Myriad Genetics Discovers Novel Hepatitis 'C' Target; Drug Development Program Has Been Initiated: PRNewswire - September 6, 2001; SALT LAKE CITY, Sept. 6 /PRNewswire/ -- Myriad Genetics, Inc. has discovered a novel drug target for the treatment of human infection by the hepatitis C virus (HCV), and has initiated high-throughput screening with its ProTrap(TM) drug screening technology, the Company announced today. The HCV target was discovered us
ViroLogic Announces New Technology to Advance AIDS Vaccine Development: Results Indicate New Assay Can Help Identify Effective Vaccine Candidates Faster and More Efficiently Than Current Methods: PRNewsire - September 6, 2001; PHILADELPHIA, Sept. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that an enhanced version of its PhenoSense(TM) HIV drug resistance assay can measure the potential effectiveness of AIDS vaccines in development faster, more efficiently and more consistently than currently used methods, according to r
First African Great Lakes AIDS Conference Organized and Sponsored By AHF Global Immunity, Community Health and Information Network (Chain), & Uganda Business Coalition on HIV/AIDS (UBC) Scheduled In Entebbe, Uganda, September 6 to 9, 2001: 20 African Countries Assemble to Attack Barriers to HIV/AIDS Treatment And Support * Ugandan President Museveni to Welcome Delegates*: PRNewswire - September 5, 2001; ENTEBBE, Uganda , Sept. 5 /PRNewswire/ -- AHF Global Immunity, an international initiative of AIDS Healthcare Foundation, together with its partners, the Uganda Business Coalition on HIV/AIDS (UBC) and Community Health And Information Network (CHAIN), are hosting the First African Great Lakes AIDS Conference in Entebbe
ViroLogic Awarded $1.2 Million Ryan White CARE Grant For HIV Drug Resistance Testing in District of Columbia: PRNewswire - September 5, 2001; SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC), announced today that the Company has been exclusively awarded a $1.2 million Ryan White CARE Grant for HIV drug resistance testing in the District of Columbia. The grant will provide testing access to low-income individuals in the D.C.
Challenge Sir Elton John and Help Fight the Battle Against: World-Renowned Musician Participates in MSN Money AIDS Market Challenge Benefiting Elton John AIDS Foundation to Increase Global Education About Life-Threatening Disease: PRNewswire - September 4, 2001; REDMOND, Wash., Sept. 4 /PRNewswire/ -- To raise funds for the prevention of and education about HIV/AIDS, Microsoft Corp. today announced the MSN(R) Money AIDS Market Challenge, featuring pop-music icon Sir Elton John. Consumers can log on to CNBC on MSN Money and learn how to improve their stock-picking skills while
Real People. Real Stories. AIDS Walk Detroit; Pontiac Woman Lost a Brother to AIDS; Her Mother Still Lives with HIV: PRNewswire - August 31, 2001; ROYAL OAK, Mich., Aug. 31 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include, Melody, whose brother d
Data Safety Monitoring Board Finds Primary Endpoint Met From Phase II Clinical Trial of REMUNE(R): PRNewswire - August 30, 2001; CARLSBAD, Calif., Aug. 30 /PRNewswire/ -- As announced by The Immune Response Corporation (Nasdaq: IMNR) on July 11, 2001, it was anticipated that the independent Data Safety Monitoring Board (DSMB) would be meeting again to evaluate the results of the Phase II clinical trial (STIR 2102) completed in Spai
The Immune Response Corporation Announces Its Decision Not to Proceed With Agouron's REMUNE(R) Study 202: PRNewswire - August 30, 2001; CARLSBAD, Calif., Aug. 30 /PRNewswire/ -- The Immune Response Corporation announced today that after a thorough review of the available data, it has informed Agouron Pharmaceuticals, Inc. (a Pfizer Company (NYSE: PFE)), the Company s former corporate partner, of the Company s decision that it does not intend, and is no
Ugandan Government and International AIDS Vaccine Initiative Sign Agreement to Accelerate Testing of AIDS Vaccines: PRNewswire - August 30, 2001; KAMPALA, Uganda , Aug. 30 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and the Government of the Republic of Uganda today signed a partnership agreement aimed at accelerating the development and testing of preventive AIDS vaccines for Uganda and the world. Uganda has been a leader in accelerating pr
Tickets Now on Sale for 'Positively Cable Aught One: The Technical Trials Of Our Sweet Cablene,' Presented by AT&T Broadband: A Benefit for Cable Positive and Denver's Rainbow House: 15 Colorado Cable All Stars Headline The 7th Annual Musical Fundraiser on October 18, 2001, in Denver: PRNewswire - August 29, 2001; DENVER, Aug. 29 /PRNewswire/ -- The work may be hard, but the laughter is cheap in the cable industry. That s reflected in prices for tickets that are now on sale for this year s Positively Cable Aught One: The Technical Trials of Our Sweet Cablene, the 7th annual musical parody fundraiser, scheduled for Thursday eveni
'Ithembalabantu!' (Zulu for 'People's Hope'); First International Partnership for HIV Treatment to Launch in South Africa: Global Immunity and the Network of AIDS Communities of South Africa (NetCom, SA) Open New AIDS Clinic Thursday August 30th: PRNewswire - August 29, 2001; U.S. Congresswomen Barbara Lee & Diane Watson, The Premiere of KwaZulu Natal Province AIDS Healthcare Foundation President Michael Weinstein to Officiate DURBAN, South Africa , Aug. 29 /PRNewswire/ -- A U.S. and South African partnership will launch a clinic to provide anti-viral HIV treatments Thursday in Durban.
Real People. Real Stories. AIDS Walk Detroit: Ten Years After Losing 2 Sons to AIDS, Waterford Woman Still Walks: PRNewswire - August 27, 2001; ROYAL OAK, Mich., Aug. 27 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Elsie, who lost 2 sons t
Three Rivers Pharmaceuticals Seeks Permission For Generic Treatment for Hepatitis C: PRNewswire - August 24, 2001; PITTSBURGH, Aug. 24 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC, a Pittsburgh-based and privately-owned company, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration ( FDA ) for permission to market the antiviral prescription drug ribavirin. Ribavirin in combinatio
Midwest AIDS Prevention Project: Detroit Artists Unite in the Fight Against AIDS At 'ARTWORKS FOR LIFE' Benefit, Saturday, September 22: PRNewswire - August 23, 2001; FERNDALE, Mich., Aug. 23 /PRNewswire/ -- Over 150 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the sixth annual ARTWORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 22, 2001 and will be held at the Edsel and Eleanor Ford House in Grosse Point
Infectech Obtains Patent in Bacterial Genomics Combating Deadly Bacteria In Patients with AIDS and Cystic Fibrosis: PRNewswire - August 22, 2001; SHARON, Pa., Aug. 22 /PRNewswire/ -- Infectech, Inc., (National Quotation Bureau: IFEC) a biotechnology company, has received U.S. Patent number 6,277,562 on August 21, 2001 for A Method for Paraffinophilic Isolation and Identification From a Body Specimen. This patent covers a method for detecting and killing non-tube
Real People. Real Stories. AIDS Walk Detroit; Local Woman Walks to Educate Latino Community: PRNewswire - August 17, 2001; ROYAL OAK, Mich., Aug. 17 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Julia, a Latino woman, w
Samaritan Pharmaceuticals (SPHC) Completes Phase I/II Clinical Trial Of ANTICORT in Patients With HIV Infection: Milestone Clinical Trial for ANTICORT, If Results Significant, Could Be First Low Cost Drug for AIDS: PRNewswire - August 17, 2001; LAS VEGAS, Aug. 17 /PRNewswire/ -- Samaritan Pharmaceuticals, Inc. (OTC Bulletin Board: SPHC), a developer of innovative treatments for high cortisol diseases, today announced it has completed its Phase Ib/IIa, dose-escalating clinical human trial for safety, toxicity and efficacy of ANTICORT(TM) in patients with HIV i
nSight Tackles The Monster Challenge: nSight and the AIDS Action Committee Team Up for the Second Time and Launch MonsterChallenge.Org, an AAC Fundraising Event Web site --: PRNewswire - August 16, 2001; BURLINGTON, Mass., Aug. 16 /PRNewswire/ -- nSight, Inc., a recognized leader in print and interactive communications offering a unique combination of consulting, project management, training, and staffing services, and the AIDS Action Committee (AAC), invite you to visit http://www.monsterchallenge.org. This whimsical,
Noted HIV/AIDS Physician to Address National Association of Black Journalists (NABJ) During Annual Conference in Orlando, FL August 23, 2001 - 8:00 a.m. : BET's Ed Gordon Will Moderate Panel Discussion: PRNewswire - August 16, 2001; OAKLAND, Calif., Aug. 16 /PRNewswire/ -- How Can Journalists Impact The AIDS Crisis? Noted HIV/AIDS physician Dr. Robert Scott of Oakland, California will lead this panel discussion, joined by award winning journalist Renee Kemp, whose coverage of the 13th International AIDS Conference in Durban, South A
Medical Services Adds Saliva-Based Rapid Test Kit: PRNewswire - August 15, 2001; EDMONTON, Alberta, Aug. 15 /PRNewswire/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has added a Saliva-based HIV test kit to its current inventory of rapid test kits. Rather than using the invasive procedure of obtaining whole blood, saliva is collected and mixed with a bu
Walter Reed Says Rapid HIV Test 100% Accurate: PRNewswire - August 14, 2001; ATLANTA, Aug. 14 /PRNewswire/ -- The test results of InstantScreen(R), a rapid HIV test kit, were presented at the 2001 National HIV Prevention Conference in Atlanta on Monday by representatives from Walter Reed Army Institute of Research. BICO, Inc. (OTC Bulletin Board: BIKO) subsidiary Rapid HIV Detection Corp. s Ins
AIDS Healthcare Foundation Alleges 'PACIFIC Doesn't CARE!' AIDS Healthcare Foundation Files Lawsuit Against PacifiCare Over Mismanagement Of AIDS Patients' HMO Specialty Referrals and Access to Appropriate Care: PRNewswire - August 13, 2001; LOS ANGELES, Aug. 13 /PRNewswire/ -- In a press conference set for 10:30 a.m. this morning, Monday, August 13th at AIDS Healthcare Foundation s HOLLYWOOD HEALTHCARE CENTER (on the campus of Queen of Angels Hospital in Hollywood, 1300 Vermont Avenue, LA, CA 90027, rear entrance) AIDS medical providers and activists will
Medical Services Completes Initial Order for Rapid Test Kits: PRNewswire - August 13, 2001; EDMONTON, Alberta, and CAPE TOWN, South Africa , Aug. 13 /PRNewswire/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, S
Kaiser Permanente Research Featured at CDC HIV Prevention Conference: Studies Find More Early Detection Needed, Barriers to Testing Can Be Reduced: PRNewswire - August 13, 2001; OAKLAND, Calif., Aug. 13 /PRNewswire/ -- Studies presented by researchers from Kaiser Permanente will be featured at the HIV Prevention Conference in Atlanta sponsored by the Centers for Disease Control and Prevention. One study will show that 40% of patients diagnosed with HIV have already progressed to AIDS before HI
Novel AIDS Research Suggests New Treatment Path; Stimulating Innate Human Immune System May Retard Disease Progression: PRNewswire - August 13, 2001; NEW YORK, Aug. 13 /PRNewswire/ -- Research published in the August issue of the peer-reviewed journal Experimental Hematology presents laboratory findings that could lead to an antibody-based medication that prevents or attenuates the progression of HIV to AIDS. This research advance is based on new insights into the e
Dixie Chicks to Perform at Gala Event to Benefit The Fight Against Pediatric Aids in Texas: PRNewswire - August 10, 2001; AUSTIN, Texas, Aug. 10 /PRNewswire/ -- Texas s most beloved chicks will come home next month to perform at the invitation only Texas Twilight Gala benefiting the Pediatric AIDS League of Texas, University of Houston Pediatric HIV Program and Pediatric AIDS Network of Dallas (PANDA). The Office of the Governor Texas Fil
Real People. Real Stories. AIDS Walk Detroit: Ferndale Man Walks in Memory of Lost Friends P: PRNewswire - August 10, 2001; ROYAL OAK, Mich., Aug. 10 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 residents from across the Metro-Detroit area whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They in
Study Published in the New England Journal of Medicine Demonstrates Durable Viral Load Suppression With Combination Regimen Containing SUSTIVA(TM) In Heavily Pre-Treated Patients: Four-Drug Regimen Containing SUSTIVA(TM)+Nelfinavir+NRTIs May Provide Effective New Option for Difficult to Treat Patients: PRNewswire - August 9, 2001; WILMINGTON, Del., Aug. 9 /PRNewswire/ -- Quadruple combination HIV therapy with DuPont Pharmaceuticals non-nucleoside reverse transcriptase inhibitor (NNRTI) SUSTIVA(TM) ( efavirenz ), plus nelfinavir and two nucleoside reverse transcriptase inhibitors (NRTIs), provides greater and more durable viral load suppression c
Effective Treatments Lacking for Most Desperate AIDS Patients; AIDS Researchers Issue Call to Action in New England Journal of Medicine: PRNewswire - August 8, 2001; PITTSBURGH -- New medications are urgently needed for individuals who have drug-resistant HIV, and academia, industry and government must work together to bring them into the clinic, urged AIDS researchers John Mellors, M.D., University of Pittsburgh, and Julio Montaner, M.D., University of British Columbia (UBC), in a
BICO Receives Order From Walter Reed for Rapid HIV Tests: PRNewswire - August 8, 2001; PITTSBURGH, Aug. 8 /PRNewswire/ -- BICO, Incorporated (OTC Bulletin Board: BIKO) announced today that subsidiary Rapid HIV Detection Corp. has received an order for 14,000 of its InstantScreen(R) Rapid HIV tests from Walter Reed Army Institute of Research for further evaluation by its HIV Research Program in Washington
The Journal of Immunology Publication Reports Power of Linkage Approach To Vaccination Over a Simple Combination of Antigen and Immunostimulatory Sequences in Mouse HIV Prophylaxis Model: PRNewswire - August 8, 2001; BERKELEY, Calif., Aug. 8 /PRNewswire/ -- Dynavax proprietary immunostimulatory DNA sequences (ISS) have been shown effective in producing potent immune responses in mice when linked to envelope protein gp120 antigen. This research appears in the August 1 issue of The Journal of Immunology. The Journal of Immunology stu
Sangamo BioSciences Reports Publication of Data in Nature Biotechnology And Methods in Enzymology: Enhanced Methods Developed to Engineer DNA-binding Proteins: PRNewswire - August 7, 2001; RICHMOND, Calif., Aug. 7 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the publication of research data in Nature Biotechnology in an article entitled, A Rapid, Generally Applicable Method to Engineer Zinc Fingers Illustrated by Targeting the HIV-1 Promoter, and related work published in Meth
Contraceptive Effective Against HIV Transmission Found Safe in Recent Testing: PRNewswire - August 7, 2001; ROSEVILLE, Minn., Aug. 7 /PRNewswire/ -- In a paper published in the current issue of the Journal of Applied Toxicology, scientists at Parker Hughes Cancer Center reported that 5-bromo-6-methoxy-5,6,-dihydro-3 - azidothymidine-5 -(p-bromophenyl) methyoxyalaninyl phosphate (WHI-07), a potent dual-function contraceptive
AIDS Healthcare Foundation Celebrates First Anniversary of Oakland, CA Earvin 'Magic' Johnson, Jr. Clinic: Growing State-of-the-Art AIDS Healthcare Facility Offers Underserved Populations in Alameda County Improved Access to Quality Care, Services: PRNewswire - August 6, 2001; LOS ANGELES, Aug. 6 /PRNewswire/ -- AIDS HEALTHCARE FOUNDATION (AHF), the nation s largest HIV/AIDS medical care provider today celebrates the first anniversary of its state-of-the-art AIDS healthcare center serving Oakland and Alameda County. The center, which opened last July and now serves 125 patients, is officiall
Pittsburgh Firm Prepares to Set the Standard in Rapid HIV Testing: PRNewswire - August 6, 2001; PITTSBURGH, Aug. 6 /PRNewswire/ -- A new weapon in the battle against the worldwide AIDS epidemic is set to be unleashed. BICO, Incorporated (OTC Bulletin Board: BIKO) subsidiary Rapid HIV Detection Corp. (Rapid Corp.) has acquired the worldwide marketing rights for a new HIV diagnostic test known as InstantScreen(R).
New Survey Reveals Most People Living With HIV Experience Anemia, Yet Few Are Aware of Its Symptoms, Diagnosis and Treatment: Know Your Red Blood Cell Count! Campaign Seeks to Increase Awareness of 'Missing Marker' for HIV -: PRNewswire - August 6, 2001; RARITAN, N.J., Aug. 6 /PRNewswire/ -- Awareness of the symptoms, diagnosis and treatment of HIV-related anemia among people living with HIV remains alarmingly low according to the results of a first-of-its-kind survey of nearly 700 HIV-positive Americans. These results indicate that, as America enters its third decade
Quidel Receives Additional Patent Protection on LTF Technology; Patent Covers Use of Company Technology to Detect Vaginal Clue Cells: PRNewswire - August 2, 2001; SAN DIEGO, Aug. 2 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced receipt of additional patent protection for its Layered Thin Film (LTF) Technology. The recently issued U.S. Patent, No. 6,200,817 B1, covers the use of proprietary Quid
Tanox to Initiate Phase I Clinical Trial of TNX-355 for HIV Infection: PRNewswire - August 1, 2001; HOUSTON, Aug. 1 /PRNewswire/ -- Tanox, Inc. (Nasdaq: TNOX) announced today that enrollment is now open in a Phase I clinical trial of a monoclonal antibody being developed for a new approach to the treatment of HIV. After review of the Investigational New Drug Application submitted by Tanox, the FDA indicat
AIDS Healthcare Foundation Announces the Opening Of The AHF Healthcare Center/New York: California-Based Provider to Join Forces With Dr. Jeffrey Greene, One of New York's Most Respected HIV/AIDS Specialists, In State-of-the-Art AIDS Healthcare Facility Offering Patients Improved Access to Quality HIV/AIDS Care, Services: PRNewswire - August 1, 2001; LOS ANGELES, Aug. 1 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical care provider is pleased to announce a new venture in the fight against AIDS. AHF is partnering with Dr. Jeffrey Greene, one of New York City s most respected HIV/AIDS medical providers in a new state-of-the-art
New Health Site Helps Consumers Interpret Lab Test Results: 'Lab Tests Online' Only Testing Site Supported By Clinical Laboratory Community: PRNewsire - July 31, 2001; CHICAGO, July 31 /PRNewswire/ -- The most up-to-date information on PSA, HIV, pap smear, cholesterol, and dozens of other laboratory tests is now a few clicks away. Lab Tests Online (http://www.labtestsonline.org ), the only non- commercial medical testing site supported by the clinical laboratory community, provides h
Health and Health Care Issues Examined at Annual Joint Statistical Meetings: PRNewswire - July 31, 2001; ATLANTA, July 31 /PRNewswire/ -- At the Joint Statistical Meetings, August 5-9, 2001, in Atlanta, Georgia, statisticians and other biomedical researchers will present recent findings in clinical research, genetics, and health policy. Paper titles of selected sessions are below, and detailed descriptions including abstr
BICO Acquires Worldwide Marketing Rights for Rapid HIV Diagnostic Test: PRNewswire - July 31, 2001; PITTSBURGH, July 31 /PRNewswire/ -- BICO, Incorporated (OTC Bulletin Board: BIKO) today announced that it has acquired the exclusive worldwide marketing rights to a rapid HIV diagnostic test, known as InstantScreen(TM), which takes only 30 seconds to produce results. Instant Screen is currently being evaluated in the l
Trinity Medical Group USA Announces Filing of New Drug Application For HIV Treatment, REMUNE(TM), in Thailand: PRNewswire - July 30, 2001; RANCHO SANTA MARGARITA, Calif., July 30 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announced the filing of a New Drug Application (NDA) with the governing health authorities in Thailand for its HIV-1 Immunogen product, also known as REMUNE(TM). The NDA, which was filed by the Comp
AIDS Healthcare Foundation Ads Target HMO Neglect of AIDS Patients: PRNewswire - July 27, 2001; LOS ANGELES, July 27 /PRNewswire/ -- A public awareness ad campaign targeting HMO neglect of AIDS-affected Californians debuts this week in major gay media outlets throughout California. The print ads -- sponsored by Los Angeles-based AIDS Healthcare Foundation (AHF) -- urge HIV-infected HMO enrollees to report problem
Camp Arroyo gives terminally ill children a place to be: PRNewswire - July 27, 2001; Justino Aguila, Chronicle Staff Writer; Eleven-year-old Dillon Scheer has to deal with the knowledge that he s HIV-positive as well as endless amounts of medications - and occasional name- calling from some classmates. But at Camp Arroyo, he s free to be a kid. Camp was fun, Dillon said while playing video games in his home in Forestville in Sonoma County.
Notable Rock Musician Scores Greatest Hit By Coming Out at HRC's Annual Chicago Dinner: PRNewswire - July 27, 2001; WASHINGTON, July 27 /PRNewswire/ -- Rock musician and Chicago native Chuck Panozzo will celebrate a special homecoming tomorrow as he comes out as a gay man living with HIV at the Human Rights Campaign s annual Chicago dinner. Panozzo, founding member and bass player of the rock group Styx, said he elected to go public
AIDS Project Los Angeles Applauds Increased Funding for AIDS Drug Assistance Program; Questions Cuts in Education and Prevention Programs: PRNewswire - July 26, 2001; LOS ANGELES, July 26 /PRNewswire/ -- AIDS Project Los Angeles (APLA) applauds Governor Gray Davis for the augmentation of the AIDS Drug Assistance Program in California s FY 2001 - 2002 Budget. The cuts to HIV prevention and education programs, however, elicited harsh criticism. Though extremely pleased with the sought